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Abstract 
 
For certain types of advanced cancers patients may be given a combination of an 
anthracycline and a taxane for chemotherapy treatment. Despite the fact that a mixture 
of anthracyclines and taxanes may be administered simultaneously to patients and that 
accurate measurement of drug levels during chemotherapy is proven to be more 
beneficial to patients, currently no chromatographic method exists for the 
measurement of any anthracycline and taxane drugs in a single assay. It would be 
useful to carry out therapeutic drug monitoring (TDM) in order to assess how the 
patient is metabolising the drugs and to see whether the dosage is working or should 
be altered. Such information during therapy can be a very important clinical tool for 
the oncologist, enabling them to change dosage or even drug regimen on an individual 
basis for patients, improving outcome in the long run. 
This thesis describes the development of two different analytical methods 
capable of quantifying both drug types in a single assay. The first method employed 
the use of on-line SPE-LC-UV and this method was then transferred to a mass 
spectrometric detector for more sensitive monitoring of the drugs. The on-line SPE-
LC-MS assay did result in lower limits of detection and was fully automated. The 
entire method of extraction, separation and detection was achieved on-line by column-
switching between an SPE column and an analytical column. The optimum type of 
switching valve, extraction conditions and separating conditions were evaluated for 
both methods in order to obtain the highest recovery possible for each target analyte 
in human serum. Recoveries ranged from 86 to 117% for each analyte in the LC-UV 
method and from 95 to 113% for most analytes in the LC-MS assay. This research 
could potentially lead to the introduction of therapeutic drug monitoring in Ireland for 
cancer patients being treated with anthracyclines or taxanes or both. 
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1.1 Research objectives and relevance of work 
 
1.1.1 Introduction 
 
The main objectives of this work were to: 
 
• Develop and validate a novel, fast SPE-LC-UV method for the quantitative 
determination of anthracyclines (doxorubicin, epirubicin and daunorubicin) 
and taxanes (docetaxel and paclitaxel) in serum. 
• Develop and validate a novel, sensitive SPE-LC-MS/MS method for the 
quantitative determination of anthracyclines (doxorubicin, epirubicin and 
daunorubicin) and taxanes (docetaxel and paclitaxel) in serum. 
 
Work was carried out in Dublin City University (DCU) School of Chemical Sciences 
and in the National Institute for Cellular Biotechnology in collaboration with the 
National Centre for Sensor Research (NCSR). 
 
 
1.1.2 Research aims 
 
The main aim of this project was to be able to quantify two types of cancer 
chemotherapy drugs in serum in a fast reliable way. The drugs under investigation are 
from the anthracycline and taxane classes of chemotherapy agents. These drug types 
can be given in tandem to treat certain types of cancer such as advanced breast or 
stomach cancer. To date, there are no methods available that can directly measure the 
concentration of both types of drug together.  
The entire method of extraction, separation and detection was to be achieved 
on-line by column-switching between a SPE column and analytical column. The aim 
was to keep run times short and recoveries of both drug class high, which was a 
formidable challenge as the anthracyclines and taxanes are chemically and structurally 
so different. The limits of detection should ideally be very low (low ng/mL range) for 
therapeutic drug monitoring. This should be easily achieved with a MS detector but 
may be difficult to attain with a UV detector. 
 
 
 
1.2 Cancer and chemotherapy 
 
1.2.1 Cancer and its treatment 
 
Cancer is one of the most traumatic diseases in our world. It involves the uncontrolled 
division of cells and the ability of these cells to spread to different parts of the body 
by invasion or by metastasis. The uncontrolled growth of cells is caused by damage to 
deoxyribonucleic acid (DNA) resulting in gene mutations that code for proteins 
controlling cell division. There are many different causes for these mutations e.g. 
exposure to radiation, smoking, hereditary factors etc. In 2004, cancer accounted for 
13% of all deaths worldwide and it is still the leading cause of death around the 
globe1. It is second only to heart disease as the largest cause of mortality in Western 
society2
.   
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There are many types of cancer, the severity of which depends on the location 
of the cancer in the body and whether there is metastasis. Many cancers can be treated 
or cured, depending on the type, location and the stage. The different types of cancers 
are either metastasis, hypoxic or proliferating cells. Metastasis is the invasion of 
tumour cells elsewhere in the body. The majority of cancer related deaths result from 
metastasis. Cancer cells leave the main tumour mass and relocate elsewhere in the 
body. The cancer cells have special proteins that can permeate a protein matrix. No 
cell death is observed with metastasis as the malignant cells are put into a state of 
stasis. It is a challenge for doctors and scientists to bring new drugs to market when 
apoptosis is not observed as clinical trials are ineffective. Hypoxic cells do not 
replicate and they exist in oxygen deficient regions of the body. Hypoxic cells remain 
inactive in the body until proliferating cells are acted upon. Once proliferating cells 
have been removed, hypoxic cells become active. There two types of hypoxia - 
chronic hypoxia and transient hypoxia. With chronic hypoxia the cells are kept a long 
distance away from the nearest vein or artery and it is permanent. Transient hypoxia 
on the other hand is only a temporary state of oxygen deficiency. The third type of 
cancer cells are proliferating cells which are rapidly dividing. They are the easiest to 
target. Cell replication can be prevented by inhibiting DNA synthesis or by 
microtubulin inhibition to kill the cells. 
Typical treatments for cancer include surgery, radiotherapy or chemotherapy. 
The course of treatment is usually dependant on the type of cancer. The aim of 
surgery is to attempt to completely remove the tumour. However, if the cancer has 
metastasised to different parts of the body before the surgery, complete removal of the 
tumour is often impossible. Radiation therapy uses ionising radiation to kill and 
reduce the size of the tumour. The effects of radiotherapy are localised to the site of 
the tumour site but the treatment can be used to treat just about every type of solid 
tumour. Chemotherapy involves the treatment of cancer with anti-cancer agents that 
can destroy cancer cells. These type of drugs attack rapidly proliferating cells. 
Unfortunately however, healthy tissue is often damaged alongside the cancerous cells 
resulting in unwanted side effects for the patient. With chemotherapy drugs there are 
also serious issues around toxicity, allergic reactions and intolerance. Being so 
cytotoxic, chemotherapeutic agents are usually administered at low concentrations 
and in small doses. In order to minimise adverse effects and maximise patient 
response, therapeutic drug monitoring (TDM) is sometimes exploited in the 
chemotherapy setting so that the concentrations of the drugs and/or their metabolites 
can be monitored in the individual patient. Inter patient variation in pharmacology is 
the primary rationale for TDM. This information can be used to tailor dosing, 
minimise side effects and even allows early intervention by the clinician for change of 
regimen if required. Modern studies have suggested that an improved 
chemotherapeutic effect is observed (efficacy, morbidity toxicity) when 
chemotherapy treatment is coupled with an accurate measurement of the required 
drugs 3. To this end, reliable, sensitive and accurate analytical techniques are needed 
to support this effort.  
In patients with advanced cancers such as those of the brain, breast and 
stomach, it is common that a patient be administered a combination of anti-cancer 
agents. TDM in these cases is even more challenging since the chemotherapeutic 
agents normally have different physiological characteristics and clinical behaviours. 
This makes it very difficult for the analytical chemist to develop one assay that is 
capable of determining the drugs simultaneously under the same conditions of 
extraction and separation.      
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1.2.2 Anthracycline chemotherapy 
 
Anthracyclines are broad spectrum chemotherapy drugs. They were originally 
developed as antibiotics but are far too toxic to be used as such. They are 
aminoglycosides bearing a tetracyclic quinine structure. They were originally isolated 
from a pigment-producing Streptomyces and are among the most widely used anti-
cancer agents 3. The principal anthracyclines are epirubicin (Epi) doxorubicin (Dox) 
and daunorubicin (Dnr). As molecules, anthracyclines are polar and weakly basic 
drugs (See Figure 1.1).  
 
 
 
 
Figure 1.1: Structures of three main Anthracyclines 
 
They are an important group of chemotherapy agents and have been used in 
cancer chemotherapy for more than 30 years and are considered to be among the most 
useful antineoplastics. Dnr was the first anthracycline to be isolated (1963) and found 
to be active against a variety of cancer cell lines. Dox and Epi were the next two 
anthracyclines to be discovered in 1968 and 1975 respectively. Idarubicin, a fully 
synthetic Dnr analogue was isolated in 1976 but it is rarely used in chemotherapy. 
Most advanced breast or stomach cancer patients treated with systemic cancer 
chemotherapy are given an anthracycline at some point during therapy 4. 
Anthracyclines all typically have a common 7, 8, 9, 10-tetrahydrotetracene-5, 12 
quinone structure, which is tailored to a sugar to form an antibiotic with anticancer 
activity 5.  Epi is the 4′-epimer of Dox and a semi-synthetic derivative of Dnr. At 
equimolar doses, Epi is less myelotoxic than Dnr and Dox and has a lower incidence 
of cardiotoxicity 6.  
As a result of the reorientation of the hydroxyl group in the 4'-position of the 
daunosamine ring, Epi has several different pharmacological properties than Dox. It 
has a lower pKa than Dox. (7.7 versus 8.4) Consequently, Epi is more lipophilic and 
better able to penetrate cells Epi also has a more favourable therapeutic index than 
Dox and can be given at higher doses3.  
Anthracyclines have an almost unlimited potential for structural modification 
due to their complex structures. Epi and Dox only differ structurally at the 4’ C 
position with the hydroxyl group (OH) in the axial orientation for Dox and in the 
equatorial orientation for Epi. Despite this minor structural difference the resulting 
product 4-epi-doxorubicin (Epi) has significantly less toxicity to bone marrow and 
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myocardium6 but comparable efficacy in a variety of solid and hematologic 
malignancies, including non-Hodgkin’s lymphoma, carcinoma breast, ovarian cancer, 
small- and non small-cell lung cancer, gastric cancer, and nonresectable 
hepatocellular carcinoma8.  
Anthracyclines have a broad range of activity against a variety of solid cell 
malignancies, such as tumours of the breast, lung, ovary, head and bladder. They are 
the most effective single agents against soft tissue sarcomas in adults 7.  
 
The side effects of anthracyclines include: 
• Myelosuppression (the most severe side effect) 
• Stomatitis 
• Nausea and vomiting 
• Cumulative dose-related cardiotoxicity 2,7 (the most serious side effect) 
 
Despite their high toxicity and multidrug resistance, the anthracyclines have a 
narrow therapeutic range. Many efforts are now ongoing to reduce the side effects in 
patients by using novel formulations which are able to release the drug in the most 
appropriate way in the body and by monitoring the quantity of anthracyclines and 
their metabolites in the body fluids or tissues frequently and in every patient to 
maintain the drug concentration within the expected range. 
The antineoplastic effects of Epi occur through numerous mechanisms. First, it 
intercalates between DNA nucleotide base pairs resulting in the inhibition of DNA, 
RNA, and protein synthesis. Second, intercalation leads to topoisomerase II cleavage 
of DNA, which results in cytocidal activity. Epi inhibits DNA helicase activity, which 
ultimately interferes with replication and transcription 7. 
Anthracyclines prevent cell division by disrupting the structure and function of 
DNA. They are classed as topoisomerase II (TOPO-2) inhibitors. TOPO-2 can induce 
double stranded DNA cleavage which is essential for the knotting or unknotting of 
circular DNA and the introduction or removal of supercoils. TOPO-2 is essential for 
proper chromosome structure and segregation. TOPO-2 promotes cell survival, 
because of this it is an excellent target for anticancer agents. The anthracyclines fall 
into the category of TOPO-2 poisons. They stabilise the cleavable complex. The 
anthracyclines act as a type of TOPO-2 poison work by binding to the enzyme DNA 
complex at the strand cleavage stage forming a cleavable complex which results in a 
permanent strand break in the DNA strand which ultimately leads to cell death 8. 
 
Maximum anthracycline activity is seen in the S-phase of the cell cycle: 9, 10 
• Intercalation of the chromophore between DNA strands and binding of the 
amino sugar with the DNA backbone causing disruption of the TOPO II 
function resulting in DNA strand breaks and apoptosis. 
• Free radical formation. Microsomal enzymes form alkylating free radicals 
such as hydrogen peroxide. 
• Hydroxyl radicals are formed by metal ion chelation which damages DNA and 
is thought to be responsible for cardiotoxicity. 
• Direct effects on cell membranes resulting in a disruption in intracellular 
transport. 
 
The most commonly used dosage of Dox or Dnr when used as a single agent is 
between 60 and 75 mg/m2 (Epi can be given at the higher dosage of 60-105 mg/m2 
because it is less toxic) as a single intravenous injection every 3 weeks. The dose 
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administered depends on age, bone marrow density and possible prior therapy11. Great 
care should be taken when anthracyclines are administered so as to reduce the chance 
of perivenous infiltration and reduce the chances of local reactions such as blistering, 
ulceration or urticaria.  
Immediate gastrointestinal toxicity with nausea is observed soon after 
administration of anthracyclines. An early clinical study of Dnr in adults and children 
with acute leukaemia found that bone marrow suppression was the predominant 
toxicity. Other toxic effects described were severe local reaction following 
extravasation, infectious complications, oral ulceration and alopecia10. Bone marrow 
suppression caused by anthracycline administration limits dose intensity. The major 
dose limiting toxicity however is cardiotoxicity. This cardiac damage is believed to be 
caused by metabolic free radical formation. The most significant form of 
cardiotoxicity seen from anthracycline administration is a cardiomyopathy which can 
lead to congestive heart failure in some cases 9. 
Despite the cumulative toxicity associated with anthracyclines they are among 
the most active chemotherapeutic drugs and can be administered in a safe, well 
tolerated way providing lifetime exposure to the drug is monitored and alternative 
drugs used when the threshold for cardiotoxicity is reached 9. 
Doses of Epi appear to be less cardiotoxic than equivalent cumulative doses of 
Dox. In a radomised study of adjuvant chemotherapy in Canada including 380 
patients who received 300 – 400 mg/m2 of Epi in the FEC (5-Fluorouracil, epirubicin 
and cyclophosphamide) regimen, only one case of cumulative heart failure (CHF) was 
reported. In another where patients received up to 608 mg/m2 no cases of CHF were 
reported out of 351 patients on an FEC regimen. These and other similar data resulted 
in the safe threshold dose of 900 mg/m2 for Epi which is considerably higher than the 
safe threshold does for Dox (450 – 600 mg/m2) 9. 
A possible explanation for the differing cardiotoxities between Epi and Dox is 
their pharmacokinetics. Both drugs are eliminated by a three compartment model but 
there is evidence that Epi is cleared more rapidly. Plasma half life is between 8 and 25 
and 1.5 to 10 hr for Dox and between 3.1 and 4.8 and 1.1 to 2.6 hr for Epi 
respectively9.  
 Anthracyclines may be administered to patients suffering from tumours of the 
head, neck, ovary, lung and breast. Anthracyclines are very cytotoxic agents and an 
accurate measurement of their circulating concentrations and metabolically 
transformed compounds is required by the clinic 7. Often metabolites formed are 
active and toxic themselves. Anthracycline drugs are metabolised differently by 
person to person so their actual concentration has to be determined for everyone. 
Between 3.5–5.7% of administered doxorubicin, 11% of Epi, and 13–15% of Dnr are 
excreted unmetabolised via urine 12. Doxorubicinol, the main metabolite of 
doxorubicin is 10 times more toxic that doxorubicin itself and is believed to cause the 
cardiotoxicity related to Dox12.  With the development of increasingly more potent 
molecules the need for robust accurate and sensitive methods to quantify them is 
required so that their concentration levels in the body can be monitored. Many 
analytical methods have been described that are capable of monitoring the amount of 
anthracyclines present after administration. 
As a consequence of the lack of new anthracyclines coming on stream into 
common clinical practice, the main interest area is actually in the determination of the 
concentration of the drugs in biological samples using fast and reliable methods4. It 
has been shown that the clinical efficacy of the anthracyclines is related to their actual 
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concentration in the tumour tissue. This parameter varies from patient to patient and 
should be evaluated for everyone individually. 
 
 
1.2.3 Taxane chemotherapy 
 
The taxanes are also widely used as chemotherapeutic agents. The taxane docetaxel 
(also known as Taxotere) and paclitaxel (also known as Taxol) are the best known of 
this class. The naturally occurring paclitaxel (Pac) was the first taxane to be isolated 
from the bark of the Pacific yew tree in the 1960s. It was approved for use in 
December 1992. Docetaxel (Doc), a semi synthetic analogue of Pac, was first 
synthesised starting from 10-deacetyl baccatin III, a non-toxic precursor found in the 
European yew (Taxus baccata) in 1986. Pac and Doc are both types of diterpene 
alkaloid plant extract. These drugs have contributed significantly to the treatment of a 
variety of malignancies, such as ovarian, breast, and non small cell lung cancers, as 
well as head and neck cancer and some cancers of the digestive system13. Taxanes are 
of relatively large molecular weight (>800) and non-polar in nature (See Figure 1.2). 
 
 
    
Figure 1.2: Structures of two main Taxanes 
 
Taxanes are inhibitors of microtubule depolymerisation14. Microtubules are 
amongst the most strategic subcellular targets for anticancer agents and they are found 
in all eukaryotic cells. Microtubules are composed of tubulin dimers and there is a 
continuous dynamic equilibrium between the dimers and the microtubules. Any 
disruption of the equilibrium within the microtubule system disrupts cell division and 
the normal cellular activities in which microtubules are involved 15. The taxanes 
promote the polymerisation of tubulin into stable microtubules and inhibit 
microtubule depolymerisation, thereby inducing the formation of stable microtubule 
bundles which in turn leads to cell apoptosis (see Figure 1.3). Once the microtubules 
are not broken down the cancer cells become so clogged with microtubules that they 
cannot grow and divide. 
Microtubules consist of long, filamentous protein polymers having important 
functions in cellular activities such as, maintenance of cell shape, cellular movement, 
cell signaling, division and mitosis. These roles make microtubules a highly effective 
cancer target. Both Pac and Doc bind to the beta subunit of tubulin but the 
microtubules produced by Doc are larger than those produced by Pac. Doc binds more 
avidly to tubulin than Pac does and is retained intracellulary for longer. This could be 
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a possible explanation as to why Doc appears to be up to 2 or 4 times more potent 
than Pac in antitumour efficiency studies 16. 
 
Normal Case: 
  
 
 
In presence of Taxane: 
 
 
Figure 1.3: Effect of Taxanes on cancer cells 
 
 
The side effects of taxanes include: 
• Myelosupression 
• Dose limiting neuteropenia  
• Fluid retention 
• Hypersensitivity reaction 
 
Taxanes are lipophilic and very hydrophobic. A safe method of getting the taxanes 
into solution had to be found for intravenous injection or its chemotherapeutic effect 
would be of no use. Often taxanes are dissolved in an elixir of castor oil known as 
Cremophor EL. The castor oil is believed to cause many of the unwanted side-effects 
associated with taking Pac including nausea, vomiting, joint pain, appetite loss, brittle 
hair and tingling sensations in hands and feet (neuropathy) 17. The observation of 
hypersensitivity reactions when taxanes are administered in early phase one trials led 
to a prolonging of infusion time to 6 or 24 hrs. These reactions may be attributed to 
the taxane itself or to the formulation vehicle. In later trials involving Pac the infusion 
time was reduced to 3 or 1 hours. Neuropathy and myalgia were the most significant 
side effects observed at this lower infusion time. Incidences of hypersensitivity did 
not differ significantly between short or long infusion times. Neutropenia is the major 
dose limiting factor when administering taxanes (85% of patients given 100 mg/m2 of 
Doc and 75% of patients given 60 mg/m2 of Doc). Patient blood count must be 
frequently monitored so that drug dosage can be altered.  
Most commonly, Pac and Doc are administered intravenously as a single agent 
or in combination with other chemotherapeutic drugs depending on the type and stage 
of cancer in doses of between 75-135 and 75-100 mg/m2 over a particular time scale. 
Patients treated with taxanes are often pre-medicated with a dose of corticosteroids to 
ease the side effects of hypersensitivity reactions and fluid retention 18.  
Taxanes are highly protein bound (Pac 95%, Doc > 90%)16. Tissue distribution 
and binding influence the rate of plasma clearance. Pac plasma clearance follows non-
linear kinetics; hence, the severity and duration of toxicity increase disproportionately 
with dose escalation. In contrast, Doc follows linear kinetics within the clinical dose 
range of (55 to 115 mg/m2); its concentration changes linearly with changes in 
dosage16.  
 
Tubulin 
(monomer protein) 
Microtubulin 
(polymer) 
Stable microtubulin 
bundles 
(Size 22 A) 
 
Microtubulin 
(polymer) 
Normal cell 
cycle 
Defective cell 
Cycle (Apoptosis) 
Tubulin 
(monomer protein) 
 
Microtubulin bundles 
(Normal size 24 A) 
 16
Taxanes are metabolised primarily in the liver by cytochrome P450 
enzymes19. These P450 enzymes metabolise Pac to different forms of 
hydroxypaclitaxel; 6α-hydroxypaclitaxel, and p-3‘-hydroxypaclitaxel20 (depending on 
the enzyme) which in turn is further oxidised to dihydroxypaclitaxel. Pac and its 
metabolites are excreted in the faeces, but studies have shown that only Pac is toxic, 
its metabolites are inactive 19.  
As with the anthracyclines, much work is being put into developing novel 
formulations for drug release and into the determination of the concentration of these 
drugs in biological samples using fast and reliable methods.  
 
 
1.2.4 Combination chemotherapy 
 
For certain types of cancer, especially for cancers at an advanced stage, regimens 
containing multiple anti-cancer drugs are typically employed. For example, the 
combination of an anthracycline and a taxane (mainly Epi and Doc) is one of several 
standard treatments administered to patients suffering from advanced breast or 
stomach cancers 21, 22. In recent years, the need has grown for an individualised 
patient dosage system as modern studies have suggested that an improved 
chemotherapeutic effect is observed (efficacy and morbidity) when chemotherapy 
treatment is coupled with an accurate measurement of the required drugs and/or their 
metabolites 22. This is even more important when drugs are given in combination 
since there may be further interactions between them resulting in more metabolites 22 
and they can also affect each other’s action and metabolism. However, assays capable 
of determining different classes of drugs simultaneously are not common due to the 
difficulties encountered during analytical development in terms of extraction, 
separation and detection. 
 
 
 
1.3 Analytical separation and extraction techniques 
 
1.3.1 Separation techniques 
 
There are a number of separation techniques which can be used for determination of 
drugs in biological matrices. A separation technique which offers certain advantages 
for bioanalysis is capillary electrophoresis (CE). Some of the best known are based on 
chromatography and include gas chromatography (GC) and liquid chromatography 
(LC).  
Electrophoresis is based on the movement of electrically charged particles 
under the influence of an electric field. The separation is based on the different rates 
of migration of solutes. When an external electric field is applied to a solution of 
charged particles, each ion moves towards the electrode of opposite charge. Their 
individual rates of migration depend on their environment, their size and the strength 
of electric field. 
 In GC a sample is vaporised and injected onto an analytical column. The 
injected sample is then transported through the column by the flow of an inert gas 
acting as mobile phase. Commonly used carrier gases include nitrogen, argon carbon 
dioxide and helium. Columns are generally coated with a liquid stationary phase. 
Column temperature depends on the boiling point of the sample vaporised. There are 
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many different types of detector that can be used in conjunction with GC including 
flame ionisation, flame photometric, electron capture and thermal conductivity 
detectors. The type of detector used depends on the sample and the separation 
conditions.  
By far the most commonly employed separation technique for bioanalysis is 
that of LC. LC, often called high performance liquid chromatography (HPLC), is an 
analytical process that separates a mixture into its individual components and often 
enables both their identification and quantitation. The basic components of any LC 
system are a pump/solvent delivery system, injector, analytical column (stationary 
phase), detector and a PC (see Figure 4). The mobile phase, which contains the 
sample, is pumped through the system and interacts with the stationary phase which is 
the ‘heart’ of the system. The column packed with stationary phase is where the 
separation occurs. The separated components are then ‘seen’ by the detector before 
flowing to waste or a fraction collector. There are many different types of detector 
that can be in LC including UV-Vis, fluorescence and mass spectroscopic detectors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Schematic of a HPLC system 
 
 
There are many different modes of LC including size exclusion, affinity 
chromatography, chiral chromatography, normal phase and reversed phase. 
 Size exclusion chromatography (SEC) is a useful technique for separating 
components with a significant difference in molecular weight. There are two types of 
SEC, gel filtration chromatography (GFC) and gel permeation chromatography 
(GPC). GFC uses an aqueous mobile phase and hydrophilic packings used to separate 
biological macromolecules. In GPC an organic mobile phase and hydrophobic 
stationary phase is used. One of the major roles of SEC is in the separation of 
polymers. 
 Affinity chromatography is based on the ability of biological molecules to 
recognise and bind to other molecules in a specific way. It takes advantage of a ‘lock 
and key’ binding model (see Figure 1.5). An affinity ligand e.g. an antibody, that is 
specific for a single type of biological molecule e.g. an antigen, is covalently bound to 
an inert support. A sample mixture containing the biomolecule of interest is applied to 
the column where only the biomolecule binds to the affinity ligand while the rest of 
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Waste 
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the sample flows through the column. Interactions between the ligand and target 
molecule can occur through hydrogen bonding, van der Waal’s forces, electrostatic or 
hydrophobic interactions. The target molecule can be eluted simply by reversing the 
interaction between ligand and target molecule, by changing the pH or polarity or by 
introducing a competitive ligand. The technique is often used for protein purification 
and acts as a preconcentrating step also.  
 
 
 
 
 
 
 
 
Figure 1.5: Affinity chromatography retention mechanism 
  
In chiral chromatography enantiomers are separated based on their 
stereoselectivity. To separate enantiomers they must be changed to diastereomers. 
Enantiomers can be derivatised to diastereomers with a chiral selector. Chiral LC can 
be performed in three different ways. There is a pre-separation derivatisation 
approach which creates diastereomers before separation, a chiral stationary phase and 
an achiral mobile phase can be used or chiral selectors can be added to the mobile 
phase in conjunction with a regular stationary phase. 
 With normal phase chromatography the dominant mechanism at work is 
adsorption. It utilises a polar stationary phase and a non-polar mobile phase. This type 
of chromatography is used to separate very hydrophobic compounds which would 
have a very weak interaction on a highly polar stationary phase and hence be eluted 
quickly. Normal phase chromatography is best suited to the analysis of compounds 
that are soluble in non-polar solvents.  
Reversed phase chromatography is the most commonly used due to its 
versatility and suitability for drug compounds. In the reversed phase mode of LC, the 
stationary phase is non-polar while the mobile phase is polar. Based on the interaction 
of ‘like dissolves like’, the more polar compounds will spend more time in the mobile 
phase and will flow through the system quickly, reaching the detector quickly. The 
less polar compounds will spend more time interacting with the stationary phase and 
will be retarded on their journey through the column, reaching the detector more 
slowly. This difference in solubility between the analytes in the mixture effects their 
separation. From the analytical point of view, judicious selection of stationary phase 
and correct choice of mobile phase composition and proportion will be the 
cornerstone of good method development. Silica is most commonly used as the base 
stationary phase in LC columns as it can cope with the high pressures involved, it is 
chemically inert, it is abundant and cheap and functional groups can be easily bonded 
to its surface creating a huge array of LC columns. The most popular columns for 
reverse phase LC are the bonded phases of C8 and C18, which are chains of eight and 
eighteen carbons length respectively. See Figure 1.6 for a schematic of reversed phase 
chromatography. 
 
Affinity ligand (∆) 
 
Sample mixture added Complimentary species binding Remaining sample mixture 
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Figure 1.6: Schematic of reversed phase chromatography 
 
In LC, the mobile phase may be pumped through the column isocratically or by 
gradient elution. Isocratic pumping, the simpler of the two, involves the use of a 
single mobile phase being pumped through the system and the solvent composition 
remains constant throughout the analysis. Gradient elution, on the other hand, is 
useful if the solvent composition needs to change during a run. This might be required 
if there are a large number of compounds to separate, if peaks are not well resolved, 
from each other, or if the analytes of interest are structurally very different. 
 
 
1.3.2 Detection techniques 
 
The choice of detector used in LC is very important both qualitatively and 
quantitatively. The most readily available detector is the UV-Vis detector. Any beam 
of electromagnetic radiation passing through the detectors flow-cell will cause a 
change in its intensity. A UV-Vis detector uses light from the visible and UV regions 
of the electromagnetic spectrum. It has almost universal applicability, responding to 
any compound which absorbs radiation in the region of approximately 200-800nm. 
Absorbance of electromagnetic radiation in this range corresponds to the excitation of 
the relatively low energy electrons such as pi-electrons, or non-paired electrons of 
some functional groups. For example, any compound with a benzene ring will have an 
absorbance at around 210nm and 250nm. If a parent compound has a good response 
using this type of detector, it may also be very useful for the detection of metabolites, 
impurities and other related substances since the spectra of these compounds will be 
similar enough to be detected. Advantages of this detector include wide linear range, 
wide applicability and ease of use. Disadvantages include lack of sensitivity and 
selectivity.  
Approximately 10-15% of compounds are thought to fluoresce and for these 
molecules, a fluorescence detector can be very useful offering low detection limits 
due to low background. In fact, laser induced fluorescence (LIF), an expensive 
version of this detector, is the most sensitive detection technique available. 
Disadvantages include narrow linear range and narrow applicability, meaning that 
even if it works well for a parent compound, it may not respond to its related 
substances.   
E
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A more recent detection tool for LC is the mass spectrometer (MS). MS 
measures the mass to charge (m/z) ratio of ions so any molecule which can be ionised 
will respond to this detector. A mass spectrometer must create charged particles (ions) 
from molecules entering from the LC instrument. It then examines those ions to 
obtain information about the molecular weight of the compound and its chemical 
structure. The principal components of a mass spectrometer are a sample introduction 
device (interface), an ionisation source, a mass analyser and an ion detector (see 
Figure 1.7).  
 
 
Inlet Ionisation  source 
Mass 
analyser Detector 
Data 
system 
All  ions Selected  ions 
ESI – For any size, mainly polar molecules. 
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Quadrupole – High resolution, good for quantitation 
 
Ion trap – Sensitive and compact, good for structural 
 elucidation 
 
Time of flight – Very fast, limitless mass range 
 
 
Figure 1.7: A schematic of the principle components of a MS 
 
There are a number of types of ionisation sources and mass analysers available, 
depending on application. All LC-MS interfaces have to be able to evaporate liquids 
to gases, ionise neutral molecules to charged species and maintain the required 
vacuum for mass analysis. 
The three main types of ionisation sources used prior to an LC instrument are 
electrospray ionisation (ESI), atmospheric pressure chemical ionisation (APCI) and 
matrix assisted laser desorption ionisation (MALDI). However MALDI is not very 
easily hyphenated to an LC system and it is generally used as an off-line detection 
system for LC. 
ESI is one of the most exciting ionisation techniques to arrive. ESI generates 
ions directly from solution (usually an aqueous or aqueous/organic solvent system) by 
creating a fine spray of highly charged droplets in the presence of a strong electric 
field (typically 3.5 kV). As the droplet decreases in size, the electric charge density on 
its surface increases. The mutual repulsion between like charges on this surface 
becomes so great that it exceeds the forces of surface tension, and ions begin to leave 
the droplet. The ions are then electrostatically directed into the mass analyser by use 
of applying the opposite charge to the capillary which pulls the ions into the mass 
analyser. Vaporisation of these charged droplets results in the production of gaseous 
ions. As well as forming a gas from the liquid phase, the ESI chamber evaporates the 
LC mobile phase, both processes aiding the ionisation process. See Figure 1.8 below 
for a schematic of an ESI chamber. 
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Figure 1.8: Schematic of an ESI chamber 
 
The number of charges retained by an analyte can depend on such factors as 
the composition and pH of the electrosprayed solvent as well as the chemical nature 
of the sample. For small molecules (< 1000 Da) ESI typically generates singly 
charged ions, for medium sized molecules of 1000-2000 Da, ESI generates single or 
double charged ions while for large molecules (> 2000 Da) the ESI process typically 
gives rise to a series of multiply-charged species. Because mass spectrometers 
measure the mass-to-charge (m/z) ratio, the resultant ESI mass spectrum contains 
multiple peaks corresponding to the different charged states. Such spectra can be 
deconvoluted to yield a molecular weight even for large proteins and other 
biomolecules.  
ESI allows for very sensitive analysis of small, large and labile molecules such 
as peptides, proteins, organometallics, oligosaccharides, and polymers. Another 
advantage of ESI-MS is that ions are formed directly from solution, a feature that has 
established the technique as a convenient mass detector for LC. While past attempts to 
couple liquid chromatography with mass spectrometry resulted in limited success, ESI 
has made the technique of LC-MS much more prevalent in analytical laboratories and 
research centres.  
APCI is another very commonly used ionisation technique. In APCI the eluent 
is introduced to the interface using a capillary of a similar design of that used in ESI. 
In APCI the emerging liquid from the capillary is surrounded by a heated inert 
nebulising gas instead of a potential applied to the capillary like in ESI. The 
nebulising gas and heat form an aerosol that begins to evaporate. There is a pin placed 
in the heated region with a high potential applied to it that produces an electrical 
discharge that can ionise solvent molecules. Ionised gas plasma is formed by a 
combination of collisions and charge transfer processes. Molecules eluting into this 
gas plasma can become ionised by proton transfer. The rate of evaporation required to 
ensure that all species are in the gas phase as they reach the discharge pin is 
determined by the rate of flow of eluent into the heated region. Stable droplet 
formation is required to ensure that a stable plasma of ionised solvent molecules 
exists around the discharge pin so that the same discharge conditions affect all 
analytes within a sample. High flow rates are used in APCI (over 1.0 mL/min) 
because at lower flow rates an unstable analyte signal is observed due to the 
instability of the gas plasma by a non-reproducible discharge process. See Figure 1.9 
for a schematic representation of the APCI process. 
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Figure 1.9: Schematic of APCI ionisation 
 
Another type of ionisation technique is MALDI where a special matrix which 
is easily energised by a laser beam is mixed with a sample of interest on a target spot. 
The energised matrix molecules in turn ionise the sample molecules they are mixed 
with and the ionised analytes of interest pass into the mass analyser. MALDI has had 
its biggest impact on the field of protein research. The ability to generate MALDI-MS 
data on whole proteins and proteolytic fragments is extremely useful for protein 
identification and characterisation.  
MALDI-ESI can be coupled to nanoscale capillary LC separations. It can be 
coupled as LC-ESI-MS/MS for more expansive protein characterisation by 
performing a post column flow split, with an aliquot going to the ESI source and an 
aliquot spotted onto MALDI targets off-line. This has been done by Bodnar et al 23 to 
evaluate the improvement of proteome coverage of protein mixtures when both 
MALDI and ESI are combined. 
Depending on the information required from the ionised analytes, there are a 
number of types of mass analysers. For structural information, an ion trap would 
probably be the analyser of choice. An ion trap is a small chamber that uses RF and 
DC voltage to ‘trap’ ions. Using the electric field ions can be stored, isolated, 
fragmented, and then scanned out of the device to create a mass spectrum. Ion traps 
can carry out tandem mass spectrometric steps (MSn) but the number of successive 
fragmentation steps performed can be limited by the sensitivity and software of the 
MS. Some ion traps can perform up to MS12. This can be extremely useful for 
structural elucidation of unknown or novel compounds by sequential MS/MS 
experiments. 
For accurate molecular weight information of large molecules, a time-of-flight 
(TOF) analyser would probably be chosen. This type of mass analyser is mostly 
associated with ESI ionisation. TOF mass analysers measure the mass-to-charge ratio 
based on the length of time it takes for ions to reach the detector (their time of flight) 
in a tube. TOF analysers can be either linear or reflector based on the ions flight path. 
TOFs provide a full scan MS spectrum and high mass accuracy and resolution. 
TOF/TOF instruments are now available. 
For quantitative information, a quadrupole analyser would normally be 
favoured. The triple quadrupole is a tandem mass analyser. It consists of three 
quadrupoles in series. The first functions as a mass filter, the second as a collision cell 
and the third as a mass analyser for the chosen fragment ions. By altering the voltage 
and current, the instrument is tuned to allow only ions of a certain mass-to-charge 
ratio to travel through the first quadrupole. The second quadrupole acts as a holding 
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chamber in which a single tandem mass spectrometric experiment can be carried out. 
The final quadrupole is tuned to allow only the daughter ion of choice to reach the 
detector. Triple quadrupoles are used for determining the absolute amount of an ion in 
a sample and can be extremely sensitive. 
Advantages of the MS detector include sensitivity and almost universal 
applicability. Disadvantages include the fact that the MS is a highly technical 
instrument in its own right so an increased level of skill is required to operate this 
detector with its many types of ionisation techniques and mass analysers, and ever-
increasing array of hybrid instruments. 
 
 
1.3.3 Sample preparation techniques 
 
Before a biological sample can be analysed by LC it must first be ‘cleaned up’. This 
requires removing the drug to be analysed from the complex matrix it is mixed with 
the best recovery possible. There are many different sample preparation/extraction 
techniques available including protein precipitation (PP), liquid-liquid extraction 
(LLE) and solid phase extraction (SPE).  
PP is a well established type of extraction procedure. In essence, a solvent or 
strong acid or base are added to the biological sample which causes biological 
material, in particular proteins, to ‘crash out’ of solution creating a pellet. Following 
centrifugation, the supernatant, which should contain the majority of the analyte of 
interest, can be removed for analysis. Protein solubility in aqueous buffers depends on 
the nature of the polar and non-polar amino acids that make up the protein. A protein 
with a high content of hydrophobic amino acids on its surface will not be very soluble 
in an aqueous solution. Proteins feel both attractive and repulsive electrostatic 
processes depending on the environment they are in. PP then occurs by the addition of 
a precipitation agent (for e.g. gel beads in a gel filtration technique) to the protein 
solution. Disadvantages of PP include the fact that the extracts can still contain matrix 
components and also that the supernatant can continue to form a precipitate on 
standing. 
LLE is an extraction method that is based on mixing two immiscible liquids. 
The liquid-liquid dispersion created by mixing is then separated by gravity or by 
centrifugal force 24. For biological samples, which are aqueous based, generally an 
organic solvent is added and the mixture shaken. The drug of interest is extracted 
from the aqueous phase into the organic phase in which it has preferential solubility, 
leaving behind the proteins and lipids etc. One of the major disadvantages of LLE is 
that it is difficult to automate and organic solvent consumption tends to be high. 
Evaporation to dryness and reconstitution are also normally required (see Figure 
1.10). 
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Figure 1.10: Schematic showing the main steps in an LLE procedure 
 
SPE is one of the most common and least expensive extraction techniques. 
SPE uses a solid and a liquid phase to isolate the analyte of interest from a biosample. 
The general procedure of SPE involves four steps: conditioning, loading, washing and 
eluting (see Figure 1.11). The SPE cartridge or disc is conditioned with solvent 
(wetted) and then the sample is loaded onto the phase and allowed to pass through. If 
the phase has been correctly chosen for the analyte, the analyte will be retained by the 
phase while the rest of the biological matrix will wash through to waste. A solvent 
with an affinity for the analyte is then passed through the cartridge to elute the analyte 
in as small a volume as possible. One of the major advantages of SPE is that it can be 
automated which greatly reduces analysis time and increases throughput. The above 
three extraction procedures are usually carried out off-line, which involve a number of 
manual and sometimes labour-intensive steps. Each step can introduce errors and so 
precision can be poor. Of the three processes, SPE does lend itself to automation and 
hence on-line SPE methods have been reported in the literature. On-line approaches to 
sample clean-up offer enormous advantages of speed, improved precision, higher 
throughput of samples and unattended operation. Complex biofluids such as serum or 
plasma can be directly injected onto an on-line SPE column which is connected to the 
LC column. When ready, the extract is swept onto the LC column and the mixture 
separated and detected as normal. The same principles as off-line SPE are used except 
that instead of using an SPE cartridge (generally single use), an SPE column is used 
which allows repeated injections and larger volumes of biosample can be accepted. 
On-line methods offer higher percentage recoveries, quicker analysis time, reduced 
solvent consumption and no sample pre-treatment is required 25. However, extensive 
method development is required since there are many experimental variables to be 
investigated. 
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 25
Step 1 Step 2 Step 3 Step  4 
Condition the SPE tube Add sample Wash the column Elute target analyte 
Eluted 
interferences 
 
Figure 1.11: Schematic showing the four main steps in an SPE procedure 
 
 
1.4 Validation of analytical methods 
 
Once any analytical method has been developed, it is important to validate it 
according to recognised protocols to ensure that the specific test is suitable for its 
intended use. Reliable analytical results are required to comply with international 
regulations and to ensure patient safety. FDA regulations require that an analytical 
method be validated before and during regular routine use. While there are many 
guidelines for validation of analytical assays such as those published by the FDA, 
Institute of Validation, EU...etc, 26, 27 the most relevant protocols for bioanalytical 
work are those laid down at the Washington Conference of 1990 by Shah et al 28.   
Authors prioritise different parameters during a validation but all would agree that the 
following are all important: precision, accuracy, sensitivity, linearity and range, 
recovery and stability. In this thesis, it was decided to follow the guidelines set out by 
Shah et al 28 as this paper is highly regarded and deals with the validation of analytical 
methods. This included intra-day precision (repeatability) and inter-day precision 
(intermediate precision), accuracy, sensitivity, limits of detection and quantitation 
(LOD and LOQ), linearity and range, recovery and stability to freeze-thaw cycles. 
Each of these parameters is briefly described below. 
 
1.4.1 Precision  
 
Precision is the closeness of agreement between obtained results. It is sometimes 
described as the degree of scatter around the mean. It is expressed as a percentage of 
the relative standard deviation (%RSD) of a set of results. Precision in this thesis was 
evaluated by analysing intra-day and inter-day results. 
 
1.4.2 Accuracy 
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Accuracy is a measure of the closeness of the result to true value. It is measured by 
comparing the calculated concentration to the true (actual) concentration and 
expressing the difference between them as a percentage error. 
 
1.4.3 Sensitivity 
 
Sensitivity was evaluated by measuring the limit of detection (LOD) and the limit of 
quantitation (LOQ).  The LOD in this work was defined as the analyte concentration 
that gave a signal to noise (S/N) ratio of 3:1. The LOQ was defined as the analyte 
concentration that gave a S/N ratio of 5:1. The LOD and LOQ values were obtained 
by measuring the signal-to-noise ratio at and nearby where a target analyte eluted and 
by measuring the concentration of that analyte which was either three or five times 
that baseline noise 
 
1.4.4 Linearity and range 
 
It is important to assess the useful analytical range of the method. A wider range 
means that more samples can be measured directly and that fewer samples will 
require dilution or pre-concentration in order to bring their concentrations within the 
limits of the calibration curve. Linearity and range is determined by preparing a 
calibration curve and determining its regression coefficient. The calibration curve of 
an analytical method is, within the range, a monotonic relationship between the 
analytical signal (response) and the concentration of an analyte 29.  
 
1.4.5 Recovery 
 
Recovery is a useful way to assess how efficient an extraction procedure is. It is 
universally accepted that recovery values will be lower from biological matrices than 
from other cleaner matrices. Certainly, drugs often strongly attach to proteins and are 
therefore lost to some extent during the sample pretreatment steps due to this protein 
binding phenomenon. However, the closer the recovery value is to 100%, the better 
the sensitivity will be. Recovery values have to be reproducible to prove that they are 
accurate. 
 
1.4.6 Stability 
Storage conditions can have a big effect on sample integrity. For biofluids, the usual 
method of storage is freezing and so the ability of the samples to remain stable to 
freeze-thaw cycles was investigated.   
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anthracyclines and taxanes 
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2.1 Physiochemical properties  
 
2.1.1 Anthracyclines 
 
Anthracyclines are polar, slightly basic chemotherapeutic drugs. The anthracycline 
ring is lipophilic but there are abundant hydroxyl groups on the ring so that they are 
readily dissolved in water. Their molecular weights are 543, 543 and 527 Da 
respectively for doxorubicin (Dox), epirubicin (Epi) and daunorubicin (Dnr). They 
have a pKa of between 7.5 and 8.5. Anthracyclines are highly protein bound (>80%).  
 
2.1.2 Taxanes 
 
Taxanes are also relatively low molecular weight cytotoxic chemotherapeutic agents - 
854 and 808 Da for paclitaxel (Pac) and doetaxel (Doc) respectively. Taxanes are 
neutral to slightly basic agents and are lipophilic in nature. They are mainly soluble 
only in organic solvents. Taxanes are also highly protein bound (Pac 95%, Doc > 
90%).  
 
 
 
2.2 Sample extraction/clean-up procedures 
 
2.2.1 Anthracyclines 
 
There are three main sample extraction techniques that are usually employed to 
extract anthracyclines from biological fluids. They are liquid-liquid extraction (LLE), 
protein precipitation (PP) and solid-phase extraction (SPE).  Many examples of these 
are listed in Table 2.1. 
Wall et al 1 used LLE to extract Epi and its metabolites from serum. Epi and 
the internal standard (IS), in this case Dnr, were dissolved in human serum and water 
with ice-cold isopropanol with ammonium formate buffer for pH control. Once this 
mixture had been mixed, chloroform was added and the solution was centrifuged so 
that the layers could be separated. The organic layer containing the drugs was 
evaporated to dryness and then reconstituted in mobile phase prior to analysis. 
Recoveries of Epi from this extraction procedure were in the range of 97-122%. 
Van Asperen et al 2 also used an LLE procedure in the clean-up of Dox and 
metabolites in murine specimens. In their LLE procedure Dox and Dnr (IS) were 
added to diluted plasma and a borate buffer for pH control. Analytes were extracted 
with chloroform/1-propanol (4:1 v/v) by mixing followed by centrifugation. The 
organic layer containing the drugs was evaporated to dryness and the residue was then 
reconstituted in acetonitrile/tetrahydrofuran (40:1 v/v) with acidified water prior to 
HPLC analysis. Recoveries with this method were poorer, ranging from 66-77%. 
Based on a review of some papers that used LLE as a method of extraction for 
anthracyclines from biofluids this type of extraction technique can be time consuming 
with different recovery values being obtained. A lot of time may be required in the 
laborious sample preparation stages of an LLE method. Generally, LLE is used for 
measuring cellular levels, but it’s not ideal for serum. There is no easy way that an 
LLE extraction method can be automated. In some cases, copious amounts of organic 
solvents are consumed. Judging by the literature, LLE is not used very frequently as 
an extraction technique for anthracyclines. It may be better in terms of analysis time 
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and recovery values to avoid using an LLE extraction protocol for isolation of 
anthracyclines from biological matrices. 
Yang et al 3 developed a PP protocol prior to the determination of Dnr in rat 
plasma. A methanol/acetone (1:1 v/v) PP step was developed using 70% (w/v) zinc 
sulphate. Quality control (QC) samples were added to thawed rat plasma with 
doxorubicinol (IS). The zinc sulphate and methanol/acetone mix were added and the 
mixture vortexed and centrifuged. The supernatant was transferred to a 96 well plate 
where it was evaporated to dryness and the reconstituted in acetonitrile/water/formic 
acid (25:75:0.1 v/v/v) prior to LC-MS analysis. Recovery of Dnr after this PP step 
was about 93%. Yang reports that some PP steps can render a sample un-clean for 
mass spectroscopic analysis (in this case, the methanol/zinc sulphate washing step) 
because of severe ZnSO4 contamination. It has also been reported that some PP 
washes do not precipitate proteins fully. 
Zhou et al 4 also employed PP for the determination of Dox in rat serum and 
bile. In this method a small aliquot of the biofluid was pipetted into a polypropylene 
eppendorf with Dnr (IS) and some ice-cold methanol. The tube was then mixed and 
centrifuged before the supernatant was transferred to an autosampler vial and 
analysed by LC. Zhou et al achieved recoveries of >89% with this PP step for Dox. 
PP seems to be quite an efficient extraction technique in terms of recovery for 
the anthracyclines. Anthracycline recovery can be very high based on the papers 
discussed in Table 2.1 below. The major drawbacks with PP as an extraction 
technique are the extraction time, solvent consumption and that it is not possible to 
automate the process. While high recovery values for anthracyclines make PP an 
attractive possibility, it may be difficult to find a set of precipitating conditions for 
both anthracyclines and taxanes together.  
SPE has been the most popular method for anthracyclines to date. Mahnik et 
al 5 developed an off-line SPE procedure for the determination of these agents in 
hospital effluent. Hospital effluent and sewage water were spiked with Dox, Epi and 
Dnr in DMSO/0.9% physiological NaCl solution (1:1 v/v) to obtain samples of known 
concentrations. A C8 SPE cartridge was preconditioned with 5 mL of methanol, water 
and phosphate buffer solution (PBS) containing 2% bovine serum albumin (BSA). 
The samples were then applied to the cartridges (flow rate of about 2 mL/min). The 
cartridge was then washed with 5 mL water with any residual water washed with n-
hexane. The anthracyclines could then be eluted with MeOH/CHCL3 (1:2 v/v). The 
solvent was then evaporated to dryness and the eluate reconstituted in mobile phase 
and injected for analysis. Recovery values for all anthracyclines were >80% in the 
concentration range of 0.1 to 1.4 µg/mL and 0.1 to 0.5 µg/mL for Epi and Dox 
respectively. Using off-line SPE their extraction protocol is estimated to have taken 
about 50 min, a similar time to LLE and slightly quicker than with PP.  
 Sottani et al 6 developed a different off-line SPE method prior to LC-MS-MS 
analysis of Dox, Epi, Dnr and idarubicin in human urine with epi-daunorubicin as an 
IS. A C18 SPE cartridge was used as it was found to be the best sorbent in previous 
work. The C18 cartridge was conditioned with MeOH and equilibrated with deionised 
water. An aliquot of a urine and PBS solution was then passed through the cartridge at 
a flow rate of 0.05 mL/min with PBS. The cartridge was then vacuum dried for 20 
min before eluting the analytes with a 2-propanol/methanol chloride (50:50 v/v) 
mixture. This eluted solution was then dried and reconstituted in mobile phase before 
analysis. Recoveries for the anthracyclines ranged from 79-102% with this off-line 
SPE procedure. 
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 Off-line SPE seems to be the most commonly used extraction technique in the 
analysis of anthracyclines. It is slightly quicker than both LLE and PP with similar, if 
not higher, recoveries than the alternative extraction methods. There is less solvent 
consumption and it can be semi- or fully automated. 
All three clean-up procedures offer good recovery values but each of these 
processes is time consuming, especially when evaporation to dryness and 
reconstitution is required. Overall sample analysis time can be greatly reduced and 
precision improved if the extraction step is automated. LLE and PP cannot really be 
automated but SPE can. 
 Rudolphi et al 7 developed an on-line SPE approach to sample clean-up using 
an alkyl-diol silica (ADS) SPE column. The porous ADS was specifically designed 
for the repeated injection of biological samples, eliminating biological proteins, 
macromolecules, lipids, etc. and retaining the drugs of interest. Rudolphi used a C4 
ADS SPE column in an automated column switching LC system for the analysis of 
Epi in biological matrices. The ADS precolumn (25 x 4 mm i.d.) had bimodal 
chromatographic properties. The external (particle) bonded phase was hydrophilic and 
was non-adsorptive towards proteins. The alkyl chains on the internal surface were 
hydrophobic and allowed for RP chromatographic interactions. The sample aliquot 
(Epi in plasma) was directly injected onto the ADS by the extraction pump delivering 
extraction mobile phase of water/methanol (95:5 v/v) at a flow rate of 1.0 mL/min. 
The column was left in the ‘extraction position’ for 10 min before the valve was 
switched and an analytical mobile phase back-flushed the ADS column for 5 min 
forcing the retained anthracycline off the ADS column onto the analytical column 
where it was separated and detected by fluorescence. Recoveries of Epi ranged from 
98-106% with this on-line SPE method and extraction time was only 10 min. 
 Despite all the advantages of using on-line SPE such as the potential for high 
sample throughput, improved recoveries, better precision, reduced solvent 
consumption, Rudolphi’s paper was the only one found for the anthracyclines. This is 
probably a reflection on the increased challenges of developing such a method. 
However, once optimised, the benefits outweigh the increased development effort. 
See Table 2.1 below for a summary of extraction techniques used for 
anthracyclines in biofluids from the past fifteen years.  
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   Table 1: Reported extraction and LC detection techniques for anthracyclines from biological samples. 
 
Year Reference Anthracyclines Extraction 
Mode 
On- or 
off-line 
extraction 
Extraction Recoveries (%) Approx Extraction time (min) Detection 
 
1995 
1996 
1998 
1998 
1999 
2000 
 
2002 
2003 
2004 
2004 
 
2006 
2006 
2007 
 
[7] 
[8] 
[9] 
[2] 
[10] 
[11] 
 
[4] 
[12] 
[13] 
[6] 
 
[5] 
[1] 
[3] 
 
Epi + Met 
Epi +  Met 
Dox, Epi + Met 
Dox + Met 
Dox + Met 
Dox, Epi, Dnr, Idarubicin + Met 
Dox + Met 
Dox 
Dox + Met 
Dox, Epi, Dnr, Idarubicin 
Dox, Epi, Dnr 
Epi + Met 
Dox, Epi + Dnr 
Epi + Met 
Dnr 
 
SPE 
PP 
SPE 
LLE 
PP 
SPE 
 
PP 
PP 
SPE 
SPE 
 
SPE 
LLE 
PP 
 
On-line 
Off-line 
Off-line 
Off-line 
Off-line 
Off-line 
 
Off-line 
Off-line 
Off-line 
Off-line 
 
Off-line 
Off-line 
Off-line 
 
98-106 
94-104 
89-93 
64-77 
112 ± 6 
71-105 
 
>89 
n/a 
84-112 
79-102 
 
>80 
97-122 
93 
 
10 
>45 
n/a 
>40 
90 
>45 
 
>45 
>60 
>20 
>50 
 
>45 
>45 
n/a 
 
Fluorescence 
Fluorescence 
Electrochemical 
Fluorescence 
Fluorescence 
MS 
 
Fluorescence 
Fluorescence 
MS/MS 
MS/MS 
 
Fluorescence 
MS/MS 
MS/MS 
 
 
Key: SPE =Solid phase extraction, PP = Protein precipitation, LLE = Liquid liquid extraction, Met = Metabolites 
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2.2.2 Taxanes 
 
SPE and LLE are the two most commonly used sample clean-up techniques in the 
analysis of taxane drug molecules. PP has also been used as an extraction technique in 
taxane analysis but examples of PP sample clean-up in the literature are few and far 
between relative to SPE and LLE. 
 Vainchtein et al 14 developed an assay for the determination of Pac and its 
metabolites in human plasma using LLE as the extraction technique. Samples were 
prepared in methanol with subsequent addition of tert-butylmethylether. The samples 
were then vortexed, shaken and centrifuged before separation of the organic and 
aqueous layers. The aqueous layer was frozen in an ethanol/dry ice mixture. The 
organic layer was poured into 1.5mL eppendorf tubes. The organic solvent was then 
evaporated under nitrogen gas at 40 0C and the residue reconstituted in 100 µL mobile 
phase, 0.1M ammonium acetate/acetonitrile (1:1 v/v). The sample was then further 
cleaned by vortexing and centrifuging before 25 µL of clean supernatant was injected 
onto an LC-MS system. Recoveries ranged from 85-89% with this LLE extraction 
procedure for Pac. 
 Mortier et al 15 developed an assay for both Doc and Pac determination in 
human plasma and saliva using LLE extraction. Sample preparation was slightly 
different depending on the sample matrix (plasma or saliva). For plasma sample 
clean-up an aliquot of sample was dissolved in a water/plasma mixture (2:1 v/v). LLE 
was performed with tert-butyl ether by placing on a rotary device and centrifuging. 
The organic layer was evaporated to dryness under nitrogen at 30 0C and the residue 
redissolved in mobile phase, water/methanol/acetic acid (50:50:0.1 v/v/v) before an 
aliquot was injected for analysis by LC-MS/MS. Analysis of the saliva samples was 
complicated further by the fact that a saliva collection device had to be centrifuged, 
washed and swab centrifuged to obtain the oral fluid before the procedure outlined 
above for plasma could be implemented. Recoveries ranged from 70-101% for Doc 
and Pac in this method. 
 Recovery values of taxanes from biofluids are relatively high in the above two 
methods and in many of the LLE methods listed in Table 2.2 due to the lipophilicity 
of these drugs. However, performing the sample clean-up takes up to an hour or more 
and quite a large volume of solvent is consumed in the extraction process. Much time 
is lost mixing, shaking, vortexing, centrifuging and drying the samples.  
 Hou et al 16 developed a PP method for the determination of Doc in mouse 
plasma by LC-MS using Pac as IS. A small aliquot of plasma (40 µl) and 10 µl of IS 
were added to a micro-centrifuge tube. This mixture was vortexed before 100 µl of 
the methanol/acetonitrile mix was added. The mixture was then vortexed and 
centrifuged before the supernatant was transferred to vials for LC-MS analysis. 
Recoveries of between 91-100% were obtained for Doc using this simple PP 
extraction step. This PP process was quite efficient taking about 15 min to perform. 
However, throughput is low and it does not lend itself to automation. Also, finding 
suitable solvents for extracting both taxanes and anthracyclines would be difficult. 
 Andersen et al 17 developed an off-line SPE assay for the determination of 
Doc and Pac in plasma. SPE was performed on a column containing 100mg of cyano 
(CN) packing material with a 10 mL reservoir capacity (LRC-SPE columns, Varian). 
SPE columns were conditioned with 10 mL methanol and ammonium acetate (pH 5.0) 
buffer solution. Once conditioned the plasma samples could then be loaded onto the 
column. The plasma samples were then washed with ammonium acetate buffer 
solutions before being vacuum dried and hexane washed before drying again. Taxanes 
 36
were eluted with two washes of ethyl acetate before the samples were evaporated to 
dryness and then dissolved in a 40% acetonitrile solution. Samples could then be 
injected and analysed by LC-UV. Recoveries ranged from 76-118% for both taxanes 
with this off-line SPE method. 
 Suno et al 18 worked on an off-line SPE-LC-UV method in an assay to 
determine Pac in plasma with Doc as the IS. A Sep-Pak C18 SPE cartridge was 
chosen as the SPE sorbent. This cartridge was preconditioned with 10 mL methanol 
and 10 mL of 20 mM ammonium acetate buffer pH 5.0 before the taxane sample 
(prepared in methanol and added to plasma diluted with the ammonium acetate 
buffer) was applied. The C18 cartridge was then rinsed with ammonium acetate 
buffer, a diluted methanol buffer and hexane before the cartridge was vacuum dried. 
The taxanes were eluted with acetonitrile and the solvent evaporated under dry 
nitrogen at 50 0C. The residue was then re-dissolved in mobile phase before an aliquot 
was injected and analysed by LC-UV. Recoveries obtained from the C18 SPE sorbent 
are >90%. 
 The off-line SPE procedures used by Suno and Anderson et al are very 
similar. One noticeable difference is in the choice of SPE sorbent. Suno et al achieve 
recoveries of over 90% whereas Anderson obtains values in the range from 76-118%, 
perhaps because of the CN SPE sorbent. They were published relatively recently 
(2006 and 2007 respectively) and represent the most up to date off-line SPE methods 
for extraction of taxanes from biological matrices prior to the start of this project. 
 Recovery of taxane drugs from biological matrices using SPE in the above two 
methods is comparable to that when LLE is used. Sample extraction time is slightly 
quicker with an SPE extraction and less solvent is used. The main advantage of SPE, 
as discussed earlier, is that it can be automated.  
 One on-line SPE method has also been developed for the determination of 
taxanes from biological fluids. Grozav et al 19 published an assay for the 
determination of Doc and Pac (IS) in human plasma using on-line SPE prior to LC-
MS analysis. An Oasis HLB (2.1 mm × 20 mm) extraction column was used for 
sample clean-up. The packing material was poly(divinylbenzene-co-N-
vinylpyrrolidone), a macroporous copolymer, which can retain both hydrophilic and 
hydrophobic compounds under various conditions. On-line SPE was performed by 
column switching using a 2-position 6-port automated switching valve. The SPE 
column was first equilibrated for 1.0 min with the extraction solvent (water). Then an 
aliquot of the taxane in plasma sample was injected via an autosampler. It was carried 
to the extraction column by the extraction solvent where the plasma proteins were 
washed to waste leaving the taxanes retained on the SPE column. The valve was then 
switched and the elution mobile phase, methanol/water (95:5 v/v) back-flushed the 
drugs off the SPE column onto the head of the analytical column where separation 
could occur. The SPE column was reconditioned with the extraction mobile phase 
prior to the next injection. 
The flow rates of the analytical and extraction mobile phases were 
considerably different in this protocol. During the extraction stage, a flow rate of 2.0 
mL/min was used while the analytical flow rate was set to 0.25 mL/min. Total run 
time from injection to detection for this on-line taxane assay was just 7.0 min. 
Recoveries were in the range of 86 to 95% for Doc. This would suggest that on-line 
SPE is an efficient extraction technique for taxanes in terms of recovery, speed and 
sample throughput.  
See Table 2.2 below for a summary of extraction techniques for taxanes from 
recently published journals. 
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Table 2.2: Reported extraction and LC detection techniques for taxanes from biological samples. 
 
Year Reference Taxanes Extraction 
Mode 
On- or off-
line 
extraction 
Extraction 
Recoveries 
(%) 
Approx 
Extraction 
Time (min) 
Detection 
1998 
1998 
2000 
2003 
2003 
2003 
2003 
2004 
2004 
2005 
2006 
2006 
2007 
2008 
[20] 
[21] 
[22] 
[23] 
[24] 
[25] 
[26] 
[19] 
[27] 
[15] 
[17] 
[14] 
[18] 
[28] 
Doc 
Pac + Met 
Doc 
Pac 
Doc, Pac 
Doc 
Pac + Met 
Doc 
Doc 
Doc, Pac + Met 
Doc, Pac 
Pac + Met 
Pac + Doc 
Pac 
SPE 
LLE + SPE 
SPE 
SPE 
SPE 
LLE 
LLE 
SPE 
PP 
LLE 
SPE 
LLE 
SPE 
SPE 
On-line 
Off-line 
Off-line 
Off-line 
Off-line 
Off-line 
Off-line 
On-line 
Off-line 
Off-line 
Off-line 
Off-line 
Off-line 
Off-line 
92 
76-85 
99 ± 2 
83-98 
96-111 
93± 8 
92-105 
86-95 
91-100 
70-101 
76-118 
85-89 
>90 
n/a 
>30 
>100 
>30 
30 
>60 
>25 
>90 
1.4 
15 
>60 
>50 
>60 
>45 
>45 
UV 
UV 
UV 
MS 
MS 
MS/MS 
MS/MS 
MS/MS 
MS/MS 
MS/MS 
UV 
MS/MS 
UV 
MS/MS 
 
 
Key: SPE =Solid phase extraction, PP = Protein precipitation, LLE = Liquid liquid extraction, Met = Metabolites 
 
 
 
 
 38
Sample extraction by SPE took only 1.5 min in the method published by Grozav in 2004 for 
taxane analysis whereas SPE took about 10 min in the paper published by Rudolphi in 1995 for 
anthracycline clean-up. It would appear that an on-line SPE approach for the extraction of both 
anthracyclines and taxanes would be approapriate. No method has ever been published that can 
extract or separate both drug classes in a single assay, hence it was the aim of this project.  
 
 
 
2.3 Sample separation and detection approaches 
 
2.3.1 Anthracyclines 
 
Many different types of separation and detection methods have been applied to the determination 
of anthracyclines. Chromatographic variables include the dimensions and type of analytical 
column used, the mobile phase selection, flow rates etc. The detection mode also varies from 
author to author, with the majority employing MS or utilising the natural fluorescence of the 
anthracyclines.  
 Mass spectrometry is a modern detection technique which is becoming more accessible to 
analysts as its cost decreases. It is a more popular choice of detector than UV because of its 
specificity and range and its detection limits are far greater. It has been applied to the detection 
of anthracyclines by Arnold 13, Sottani 6 and Yang 3 with good sensitivity.  
Wall et al 1 reported an LC-MS method for the determination of Epi in serum. Following 
extraction, chromatography was performed on a C18 column. A mixture of acetonitrile/ 
water/formic acid (72:28:0.1 v/v/v) at 0.2 mL/min was used for separation. Epi was analysed by 
atmospheric pressure chemical ionization (APCI) MS and data collected in selected reaction 
monitoring (SRM) mode and over the scan range m/z 200–700. The breakdown patterns of the 
Epi and Dnr (IS) adducts were from 544  397 [M+H+] and from 528  363 [M+H+] 
respectively. Even though a mass spectrometer was used for detection, a photodiode array (PDA) 
was also interfaced to the LC-MS system to monitor the UV signal of Epi at 254 nm as it eluted. 
As anthracyclines are weakly basic drugs with pKa values in the range of 7.5-9.0, in order to 
maximise stability, ensure protonation and ionisation, improve resolution and control peak 
tailing, a mobile phase with an acidic pH was required. Mobile phase pH values between 3.0 and 
4.5 were tested by Wall et al with a pH of 3.2 delivering the optimal results for all anthracyclines 
in terms of selectivity.  
Both APCI and electrospray ionisation (ESI) were tested and it was found that APCI was 
four and seven times more sensitive than ESI for Dnr and Epi respectively. Dox was also tested 
in this research. Dox and Epi are epimers of each other so their analysis by SRM MS may be 
difficult unless they have different fragmentation patterns. It was found that while both Dox and 
Epi have a fragmentation from 544  397 [M+H+], Epi also fragments from 544  526 [M+H+] 
whereas Dox does not. See Figure 2.1 below (taken from Wall et al 1) for the fragmentation 
patterns of the epimers Dox and Epi.  
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Figure 2.1: Fragmentation patterns of (A) Epi and (B) Dox 
 
The epimers Dox and Epi can be identified and distinguished by selected reaction 
monitoring (SRM)-MS in the same run 1. SRM is used with tandem MS where the first mass 
analyser selectively only allows a single mass through to the second mass analyser for a defined 
product ion. Multiple reaction monitoring (MRM)-MS allows multiple mass ions through to the 
second mass analyser. The method was linear in the concentration range 2.5–2000 ng/ml. 
Detection limits were 1.0 and 2.5 ng/ml for limit of detection (LOD) and limit of quantitation 
(LOQ).  
Lachatre et al 11 developed a method for the simultaneous determination of four 
anthracyclines and their metabolites by LC-MS. Once the sample had been extracted from its 
biological matrix it was analysed on a column. The mobile phase was composed of 5 mM 
ammonium formate (pH 3.0)/acetonitrile (70:30 v/v) and the flowrate was 50 µL/min. ESI-MS 
was used to detect the anthracyclines. Each anthracycline and the metabolites (Dox, Epi, Dnr, 
idarubicin, aclarubicin, doxorubicinol, daunorubicinol and idarubicinol) were directly infused 
into the MS to determine their daughter ions so as to distinguish between them. The LOD for the 
anthracyclines ranged from 0.5 to 2.5 ng/mL. Retention times ranged from 10.5 to 21 min 
implying that the polarity of the anthracyclines and metabolites were quite different. Lachatre 11 
also found that, under their experimental conditions, the optimum pH for stability was between 
4.5 and 5.5 for Dnr, 3.0 and 7.0 for Dox, 4.0 and 5.0 for Epi and 4.0 and 5.0 for aclarubicin.  
The use of a fluorescent detector is quite common in the analysis of anthracyclines as 
they are naturally fluorescent molecules and low detection limits can be obtained easily without 
much interference from biological material as demonstrated by Zhou 4, Van Asperen 2, Rudolphi 
7
, de Bruijn 10 and Barker et al 8.  
Anthracyclines are also red in colour and hence absorb strongly in the visible region (see 
Figure 2.2) of the electromagnetic spectrum but no papers were found exploiting this mode of 
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detection. This detection mode may be very useful however if anthracyclines were to be 
determined in tandem with another drug class that did not naturally fluoresce. 
 
Typical UV spectrum of  
an anthracycline 
227nm 
254nm 
294nm 
480nm 
 
 
Figure 2.2: UV-Vis spectrum of Dox showing strong absorbances at 227, 254 and 294nm. 
 
Mahnik et al 5 developed an LC-fluorescence method for the determination of 
anthracyclines in hospital effluents. Following extraction from biological material, 20 µL of 
sample was separated on a narrow bore C18 column. The mobile phase consisted of a 
water/acetonitrile gradient adjusted to pH 2.0 with a 10 mM K-di-hydrogenphosphate buffer. The 
flow rate was set to 0.6 mL/min. Dox and Dnr were monitored fluorescently (excitation and 
emission wavelengths: 480 and 550nm respectively) with retention times of between 13.0 and 
16.0 min. The anthracyclines could be detected at concentrations as low as 0.1 µg/L. 
During the method development process it was discovered that while there was good 
linearity for the standard curves in plasma, the same was not true for water. Hence, waste water 
samples were spiked with bovine serum to take advantage of the high protein binding (~70%) of 
anthracyclines when performing sample clean-up.  
Kümmerle el al 12 also employed fluorescence as the mode of detection in the analysis of 
Dox in biological fluids and tissues in an isolated lung perfusion model. After sample clean-up, a 
100 µL Dox sample was analysed on a C18 column. The mobile phase consisted of a 
water/acetonitrile, 1-heptanesulfonic acid 0.2% pH 4, gradient. Dox was monitored fluorescently 
with excitation and emission wavelengths of 482 and 550 nm respectively. The method was 
linear over the range 2–1000 ng/ml in many different matrices with R2 values >0.997. LOQ was 
determined to be about 2.0 ng/mL in plasma but only about 0.1 µg/mL from tissue samples. 
 Electrochemical detection following LC has also been reported for the anthracyclines. 
Ricciarello et al 9 determined Epi and Dox and their metabolites in this manner. After SPE 
extraction the drug sample was analysed using a C18 column. A mobile phase of 
water/acetonitrile (71:29 v/v) containing 0.05M Na2HPO4 and 0.05% v/v triethylamine at pH 4.6 
was run isocratically at 1.0 mL/min to separate the anthracyclines. This method was found to be 
linear over the range of 1–500 ng/ml for all the analytes. 
 All of the methods described above for separating and detecting anthracyclines employed 
a C18 reverse phase column and used an acidic mobile phase in their separation. It is common 
practice to choose a mobile phase pH that is about 2 units above or below the pKa value of your 
target analyte. Since anthracyclines are slightly basic with a pKa value of between 7.5 and 9.0, a 
high pH mobile phase could not be used as this would destroy the silica in a conventional 
analytical column. An acidic mobile phase (pH 2.5 to 4.5) would most likely be used in the 
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separation for optimal anthracycline resolution. This is because this pH is far enough away from 
the pKa so as to ensure the anthracyclines are in one form only and the low pH also ensures 
stability for these drugs. Since anthracyclines are naturally fluorescent a fluorescent detector 
would be a sensible choice of detector as it is very sensitive and highly selective. From Table 
2.1, it can be seen that a fluorescence detector has been used quite often in anthracycline assays 
but taxanes are not fluorescent and so this detector would not be useful in a combination assay.  
 
 
2.3.2 Taxanes 
 
Numerous different LC chromatographic methods have been applied to the separation of taxanes. 
The majority of these use either UV or MS as a mode of detection. 
 UV detection is very common in the analysis of taxanes. It was used successfully by 
Sparreboom 21, Rouini 20 and Garg et al 22 to determine either Doc or Pac or both simultaneously 
in plasma as shown in Table 2.2. 
 Suno et al 18 developed a recent LC-UV method for Pac determination in human plasma. 
After SPE sample clean-up the taxanes were separated on columns packed with 
pentafluorophenyl material which is commercially recommended for taxane analysis. A 20 mM 
potassium phosphate buffer (pH 3.0)/acetonitrile (55:45 v/v) mixture was delivered at a flow rate 
of 0.25 mL/min at 45 °C for separation. The drugs were detected using UV at 230nm.  
 Andersen et al 17 also developed an LC-UV method for the determination of Doc and Pac 
in plasma. Once the drugs had been extracted from the plasma matrix they were separated on a 
C18 column. Andersen used a 20 mM potassium phosphate buffer (pH 3.0)/acetonitrile (55:45 
v/v) as mobile phase pumped at 1.0 mL/min through the column. The column temperature was 
maintained at 40 oC throughout the separation. UV detection of the taxanes was at 227nm. The 
LOQ was 0.85 ng/mL for Doc and 0.89 ng/mL for Pac. Both Anderson and Suno used the exact 
same mobile phase (at different flow rates) to separate taxanes. 
 Garg et al 22 developed an LC-UV method for the determination of Doc in urine or 
plasma. Separation was performed isocratically with an acetonitrile/0.02 M ammonium acetate 
buffer (pH 5), (43:57 v/v) mobile phase pumped through a C18 radial compression RP column at 
1.0 mL/min. All separations were performed at room temperature. The eluent was monitored by 
a UV detector at 227nm. Total run time in this LC-UV method was 13 min with retention times 
of 8.5 and 10.5 min for Doc and Pac respectively (see Figure 2.3 below taken from Garg et al 22). 
Doc is the eluted at 8.5 min, 2.0 min before Pac is eluted. This shows that Doc is the more polar 
of the two taxane molecules. 
MS is fast becoming the detection mode of choice amongst analysts working with 
taxanes because of the sensitivity associated with it, and has been used successfully by 
Alexander 26, Guo 23, Wang 25 and Gaspar et al 28 (Table 2.2) to name a few.  
 Vainchtein et al 14 developed a simple and sensitive LC-MS method for determination of 
Pac and metabolites in plasma. Once Pac had been extracted (LLE) from the plasma it was 
separated on a C18 column. The mobile phase used in the separation was 10 mm ammonium 
hydroxide in water/methanol (30:70 v/v). It was pumped at a flow-rate of 0.2 mL/min. Injected 
samples were kept cool at 10 oC. Pac was detected by positive mode ESI-MS. MS data was 
collected in multiple reaction monitoring (MRM) mode with mass transitions of m/z 854  509 
optimised for Pac, 854 being the protonated Pac adduct [M + H]+. Ammonium [M + NH4]+, 
sodium [M + Na]+ and potassium [M + K]+ adducts were also detected at 871, 876 and 892 
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respectively but at a lower intensity. Mass transitions for metabolites were also optimised. 
According to Vainchtein et al an alkaline mobile phase appeared to be most appropriate for a 
sensitive and selective detection of the Pac and its metabolites. The assay proved to be linear for 
Pac from 0.25 to 1000 ng/mL.   
 
 
Figure 2.3: LC chromatograms of (A) blank plasma and (B) a patient plasma sample containing 
210 ng/ml of Doc and 500 ng/ml of added Pac (internal standard) taken 15 min after a 1hr 
intravenous infusion of docetaxel (60 mg/m2) 22. 
 
 
 Mortier et al 15 also developed and validated an LC-MS method for the quantification of 
Doc and Pac in plasma. Once the drugs had been extracted by LLE they were separated on a C18 
column. The column and autosampler were thermostatically controlled at 25 and 10 oC 
respectively. The mobile phases composed of (A) 2 mM acetic acid/0.2 mM ammonium acetate 
in water and (B) 2 mM acetic acid/0.2 mM ammonium acetate in methanol. The gradient mobile 
phase was pumped at 0.4 mL/min. Once the taxanes were separated they were then detected by 
positive mode ESI-MS. The MRM transitions (m/z) for Doc and Pac were determined to be 
808.4  226.1, 526.9 and from 854.4  509.3, 569.0 respectively. MRM transitions of some 
metabolites were also determined. The method was found to be linear over the range of 2.0-1000 
ng/mL. Total run time from injection to detection was 11 min but the LLE sample pre-treatment 
protocol was time consuming.  
Mortier et al found they were getting a mixture of sodium and protonated adducts during 
initial method development infusion experiments. They determined that additives such as acetic 
acid and ammonium acetate aided the formation of the protonated adduct. They also looked at 
the effect of solvent type (acetonitrile versus methanol) and additives (ammonium acetate, 
ammonium formate, acetic acid, and formic acid) on sensitivity and reproducibility.  
 Parise et al 24 also developed an LC-MS assay for Doc and Pac analysis. Separation of 
the taxanes was achieved on a C18 analytical column after the drugs had been isolated from 
biological material. The mobile phase used in the separation of the two taxanes consisted of 
0.1% formic acid in methanol/water (70:30 v/v), was pumped at 0.2 ml/min. The column eluate 
was then analysed by positive mode ESI-MS. The monitored m/z adducts were 808.1 and 854.0 
for Doc and Pac respectively.  Total run time from injection to detection was 7 min with this 
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method. An off-line SPE method was used for sample clean-up. The assay was linear over the 
concentration range of 0.3 to 1000 ng/mL for Doc and 1.0 to 1000 ng/mL for Pac.  
 Reviewing methods for taxane separation, a C18 column is most frequently used. An 
acidic mobile phase is also favoured. Column dimensions and mobile phase flow rate vary 
widely among the listed methods in Table 2.2. A slower flow rate would be required if mass 
spectrometry was used as the mode of detection.  
 
 
 
2.4 Conclusions 
 
The literature reveals that there are many different methods of analysis for the determination of 
anthracyclines in biological material. The best method of drug extraction from complex matrices 
seems to be SPE. The major advantages of SPE over LLE and PP is that SPE can be automated 
providing potential for higher sample throughput, greater sensitivity, higher recoveries, less 
sample handling and reduced solvent waste. On-line SPE can greatly reduce analysis time. 
Sample clean-up can be done easily in less than 5min compared to off-line SPE, LLE or PP 
procedures that can take hours. 
 There is some variety in the type (sorbent) and dimensions of analytical column that can 
be used in the separation of anthracyclines. Judging by the majority of reviewed papers in the 
scientific literature the most commonly used LC column sorbent is C18. Most journals state that 
the anthracyclines are most stable in an acidic pH and all of the papers reviewed here chose a 
mobile phase with a pH in the range of 3.0-4.5. Although the choice of eluent varies, the organic 
solvent was predominantly acetonitrile. The majority of methods that quantify anthracyclines use 
a fluorescence detector. This is possible only because the anthracyclines fluoresce naturally. 
Unfortunately the taxanes do not. Therefore it is not possible for fluorescence to be used in a 
method to determine anthracyclines and taxanes simultaneously. The other detectors used are 
UV or MS. 
 The most common way of extracting taxanes from biofluids varies considerably. In the 
literature SPE or LLE are the most commonly used. PP can also be used but has been reported 
less frequently. Automated SPE is much quicker than off-line extraction methods as proven by 
Grozav et al 10 who reported an on-line SPE-LC-MS method for taxane analysis with a sample 
clean-up time of approximately 90 sec. For the taxanes, a C18 sorbent seems to be the column of 
choice and UV or MS the detectors of choice. 
 For the purpose of this research, it was decided that on-line SPE should be used as the 
sample pre-treatment step. It was anticipated that a major decision would be the type of SPE 
sorbent as these cartridges are generally manufactured to suit a particular type of drug 
(hydrophilic or hydrophobic for example) and anthracyclines and taxanes are chemically very 
different molecules. The many types of SPE sorbents commercially available operate under 
different principles (size exclusion, chemical interactions, etc…) and there are many different 
parameters that can be adjusted (extraction mobile phase, pH of the mobile phase, length of 
extraction, sample volume, etc…) to offer optimal recoveries for both drug classes. In terms of 
LC, it would appear that use of a C18 column with an acidified mobile phase would be a good 
starting point for separating a mixture of both anthracycline and taxane drug classes 
simultaneously. 
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As UV is one of the most readily available detectors coupled to LC and since both 
anthracyclines and taxanes could both be very easily detected in this way, it was decided to start 
method development with a UV detector.  
 MS is one of the most powerful and selective detectors available for drug analysis. It has 
been used in recent papers to quantify anthracyclines and taxanes individually and it offers low 
limits of detection. It could easily be investigated for measuring the levels of both anthracyclines 
and taxanes in serum simultaneously. The two different drug classes have very different 
ionisation conditions and fragmentation patterns but this can be accommodated in one assay 
using a state-of-the-art LC-MS system.  
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Chapter 3 
 
Development of an on-line SPE-LC-UV method for the simultaneous 
determination of anthracyclines and taxanes in human serum 
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3.1 Introduction 
 
Both anthracyclines and taxanes are very widely used classes of chemotherapeutic drugs. 
Anthracyclines have been used in cancer chemotherapy for more than 30 years, and are 
considered to be among the most useful antineoplastics. They are originally isolated from a 
pigment-producing Streptomyces1. The most commonly administered anthracyclines are 
doxorubicin, epirubicin and daunorubicin. Taxanes are also widely used. The two most 
commonly administered taxanes include paclitaxel and docetaxel. Paclitaxel was the first 
naturally occurring taxane to be discovered. It was isolated from the bark of the pacific yew 
tree2.  Docetaxel is a semi-synthetic derivative of paclitaxel and was first synthesised from 10-
deacetyl baccatin III, a non-toxic precursor found in the European yew. 
Both drug types may be used in tandem to treat certain types of cancer such as advanced 
cancers of the breast or stomach3. The drugs are administered normalised to body surface area 
but despite the fact that these drugs can be administered simultaneously, no methods currently 
exist that are capable of quantifying both drug types in a single assay. Therefore it is impossible 
to get an accurate measurement of how a patient is metabolising and reacting to this combination 
treatment. Every patient reacts differently after administration of such toxic drugs. A 
combination regimen like this may be too potent for some individuals, not potent enough for 
others and may not have the desired effect at all on others. It is for this reason that individualised 
or tailored patient dosing is recommended where possible. But in order to support this system, 
blood monitoring is required to monitor the serum levels of the administered drugs. 
Analytically, combination chemotherapy presents significant challenges since the 
different physiochemical properties of the drugs employed typically requires individual methods 
of determination. In order to develop a single assay for combinations of drugs, more extensive 
method development is needed in order to find a set of conditions that works for all analytes. 
While chromatographic methods have been reported for the determination of either 
anthracycline4,5 or taxane6,7,8 drug molecules from biological material individually, none have yet 
been developed for the two together. In this chapter, the development of an assay to extract, 
separate and detect both drug classes in a simple, precise and accurate manner is described.     
 
 
 
3.2 Scope of work 
 
The objective of this work was to develop for the first time an automated, quantitative method 
for the simultaneous determination of both anthracycline and taxane drug molecules from human 
serum using an on-line SPE-LC-UV method. Initially a UV detector was used. All five drugs 
chosen have strong UV chromophores and one advantage of UV detection is that it is readily 
available in analytical laboratories and easy to use. 
The first step involved finding a suitable analytical column and appropriate mobile phase 
to adequately chromatographically separate the polar anthracyclines and non-polar taxanes. Once 
the analytical method had been optimised, the sample extraction part of the method was 
developed. This involved choosing an SPE column and set of extraction conditions that offered a 
high recovery for both drug classes. Then, finally the overall method could be validated. 
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3.3 Experimental   
 
3.3.1 Materials and reagents 
 
Water, methanol, formic acid, ammonium formate, isopropanol, (LC grade or higher) and human 
serum were all bought from Sigma (Dublin, Ireland).Acetonitrile was bought from Labscan 
(Ireland). Dox, Epi, Dnr, Doc and Pac were all bought from Fluka Chemicals (Ireland). Patient 
serum samples containing either Doc or Epi were kindly supplied by Saint Vincent’s Hospital 
(Dublin). SPE cartridges were obtained from Phenomenex, UK (Strata-X, Strata X-C, Strata X-
CW, Strata-X-AW, Strata-C18, Strata-C18-E and Strata-SDB-L) and Chromtech, UK (Biotrap 
columns C8, C18 and MS). 
 
 
3.3.2 Instrumentation 
 
The HPLC system used in this work consisted of two Agilent 1050 pumps (one for the extraction 
solvent and one for the analytical mobile phase), a model 1050 autosampler with a 100 µL 
injection loop, a model 1050 VWA UV-Vis detector and an on-line Agilent 1200 degasser. The 
system was equipped with chemstation software version A10.01 [1635] for system control and 
data collection. A gradient LC system using an acidified water/acetonitrile mixture was used to 
separate the analytes on an Agilent Zorbax column (150 x 4.6mm I.D, particle size 5.0µm) 
packed with XDB C18 material. The extraction column used was a Biotrap 500 MS SPE column 
(20 x 4mm ID) packed with a hydrophobic polymer material and was coupled to the LC system 
via a Rheodyne 10-port 2-way switching valve (see Figure 3.1).  
 
 
 
Figure 3.1: Schematic representation of the 10-port switching valve used for on-line sample 
extraction and the resulting flowpaths in the two valve positions. 
 
 
3.3.3 Preparation of stock and standard solutions 
 
Stock solutions of epirubicin (Epi), doxorubicin (Dox), daunorubicin (Dnr), docetaxel (Doc) and 
paclitaxel (Pac), all 2 mg/mL, were weighed in a glove box and prepared by dissolving the 
Waste 
Sample In 
Analytical Column 
Detector 
Extraction Column 
Pump A 
Pump B 
Waste 
 
1
0 1 9 
8 
7 
6 
5 4 
3 
2 
Waste 
Sample In 
Analytical Column 
Detector 
Extraction Column 
Pump A 
Pump B 
Waste 
1
0 1 
9 
8 
7 
6 
5 4 
3 
2 
Valve in position one Valve in position two 
 50
compound in acidified water (adjusted to pH 3.5 with formic acid) for the anthracyclines and in 
neat methanol for the taxanes. All stock and standard solutions were stored in the refrigerator and 
protected from light. Standard solutions of the drugs were prepared (250 µg/mL) monthly by 
dilution with appropriate solution. Fresh working standard solutions were prepared daily by 
dilution of the standard solution(s) in the aqueous mobile phase to the concentrations required. 
 
 
3.3.4 Preparation of serum samples 
 
Thawed drug-free human sera samples were spiked with stock solutions of the drugs to achieve 
the final concentrations required in undiluted serum. The samples were spiked just before 
analysis.  
Patient venous blood samples were obtained from patients undergoing chemotherapy in 
St. Vincent’s Hospital, Dublin, Ireland by informed consent at 10mins after administration. The 
whole blood samples were immediately centrifuged to yield serum. The samples were kept 
frozen at -20 0C until analysed. 
 
 
3.3.5 Sample extraction and clean-up procedure 
 
Sample clean-up was performed on-line using a Biotrap 500 MS SPE column. This 
biocompatible sample extraction column allows for repeat injections of serum, plasma or other 
complex matrices directly onto a HPLC system without prior clean-up. This type of SPE column 
has a biocompatible external surface and hydrophobic internal surface. Biocompatibility is 
obtained by the attachment of a plasma protein (alpha1 acid glycoprotein (AGP)) on the external 
surface of the particles. The hydrophobic internal surface is provided by a hydrophobic polymer 
coating. The pores of the SPE column are small enough for drug molecules to permeate but 
exclude proteins and macromolecular compounds commonly found in serum or plasma that must 
be removed prior to LC analysis. The MS SPE column is stable over a broad pH range (2-11). 
The sample (standard solution or human serum) was injected onto the 100 µL loop while 
the valve was set to position one (see Figure 3.1). In this configuration, the analytical mobile 
phase was rinsing both the extraction and analytical columns. The valve was then switched to 
position two where the extraction solvent (30 mM ammonium formate/acetonitrile, 98/2 v/v, pH 
6.8) washed any macromolecular proteins in the serum to waste leaving the drugs retained on the 
extraction column. The extraction solvent was set to flow at 2.0 mL/min for 150 sec. The valve 
was then switched back to position one and an increasing gradient of acetonitrile with a flow rate 
of 1.0 mL/min back-flushed the retained drugs off the extraction column onto the analytical 
column where they were separated and detected.  
Firstly, with the valve in position one, the serum sample is introduced into the loop. Then 
the valve is turned to position two whereby extraction solvent, pumped by pump B, picks up the 
sample from loop and carries it onto the extraction column where the drugs of interest are 
retained and serum components flow to waste. During this time, pump A is rinsing the analytical 
column. The valve is switched back to position one and now analytical mobile phase, pumped by 
pump A, sweeps the retained drugs from the extraction column in back-flush mode onto the 
analytical column for separation. During this time, pump B is moving extraction solvent to 
waste.  
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3.3.6 Chromatographic conditions 
 
The gradient programme was set up as shown in Table 3.1. The extraction solvent was composed 
of 30mM ammonium formate in water/acetonitrile (98/2 v/v), pH 6.8. Mobile phase A was 
composed of 0.1% formic acid in water/acetonitrile (90/10 v/v), pH 3.5 with ammonium formate. 
Mobile phase B was composed of 0.1% formic acid in acetonitrile/water (90/10 v/v). 
 
Time (min) (Pump B) 
Extraction solvent (%) 
(Pump A) 
Mobile phase A (%) 
(Pump A) 
Mobile phase B (%) 
0 
2.5 
3.0 
16 
21 
23 
100 
100 
0 
0 
0 
100 
85 
85 
85 
25 
85 
85 
15 
15 
15 
75 
15 
15 
 
 
Table 3.1: Extraction and analytical solvent gradient timetable 
 
The monitoring wavelength was held at 254nm for the anthracyclines (13 min) and then 
switched to 234nm for detection of the taxanes until the end of the run. Separations were 
performed at room temperature. After each serum sample injected the SPE column had to be 
washed with a high percentage organic solvent to remove any retained sample. An 
acetonitrile/water (90/10 v/v) mixture was passed through the SPE column for 2.0 min to clean 
the SPE column prior to the next sample injection. This washing stage could not be built into the 
method because of software limitations. 
 
 
3.3.7 Calibration 
 
Calibration curves were prepared in drug-free serum spiked with stock solutions of each analyte. 
The concentration range tested was between 0.5 µg/mL and 25 µg/mL. Standards were prepared 
at concentrations of 0, 0.5, 1.0, 5, 10 and 25 µg/mL in water/acetonitrile (90/10 v/v). Calibration 
curves were determined by plotting peak area versus spiked drug concentrations.  
 
 
3.3.8 Method validation 
 
A full validation procedure was performed on the method including intra-day precision 
(repeatability) and inter-day precision (intermediate precision), accuracy, sensitivity (LOD and 
LOQ), linearity and range and recovery according to accepted guidelines 9. Some further 
parameters were also monitored such as stability following freeze-thaw cycles. 
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3.4 Results and Discussion 
 
3.4.1  Method development 
 
The determination of anthracyclines and taxanes simultaneously in a single assay had not been 
reported to date in any literature. A method for their extraction, separation and detection had to 
be created. Firstly, an LC column and mobile phase had to be found that was capable of 
adequately separating the five different drugs. The epimers of Dox and Epi represented a 
significant challenge here as they differed in structure only by the direction (axial or equatorial) 
of a hydroxyl group. Once a suitable set of analytical conditions had been determined, the on-
line sample clean-up part of the method had to be investigated. This involved finding an SPE 
sorbent that could extract both drug types efficiently and with high recoveries. A suitable 
extraction solvent also had to be determined, as well as timings.  
 
 
3.4.2  Choice of LC column 
 
Most published articles on work with anthracyclines or taxanes used a C18 column for their 
separation. Three different types/brands of C18 columns were tested in an attempt to separate the 
five drug compounds within a reasonable time. Columns tested included Phenomonex Prodigy 
C18 (150 x 4.6 mm, 5 µm), Agilent Zorbax XDB-C18 (150 x 4.6 mm, 5 µm) and an Agilent 
Zorbax Plus C18 rapid resolution (4.6 x 50 mm, 1.8 µm). All three columns were capable of 
separating the five different drugs but the Zorbax XDB-C18 was chosen as it offered the best 
compromise between resolution, separation time and acceptable pressure. The analytical runtime 
was 20 min with analyte retention times of around 5.9, 61, 7.0, 12.5 and 13.2 min for Dox, Epi, 
Dnr, Doc and Pac respectively. The retention factors (k) were found to be 1.3, 1.4, 1.8, 4.0 and 
4.2 for Dox, Epi, Dnr, Doc and Pac respectively with this column. Retention factors of between 1 
and 10 are considered acceptable. 
 
 
3.4.3  Selection of analytical mobile phase and UV detection 
 
Many different organic and aqueous compositions were tested in order to find a suitable 
separation mixture. Various combinations of acetonitrile and methanol in water were 
investigated at length. Eventually, a water/acetonitrile gradient was chosen as most suitable for 
the separation and resolution of all five drugs. The pH of the analytical mobile phase was found 
to control analyte retention time since the anthracyclines are extremely sensitive to pH and light. 
It is generally regarded as good practice to choose a pH that is at least two units above or below 
the pKa of the drugs under investigation. Since the pKa values of the anthracyclines range from 
about 6.5 – 8.5, it was decided to evaluate a range of pH values between 2.5 and 4.5. Further pH 
tests showed good separation of all analytes at pH 2.5, 3.5 and 4.5 (see Figure 3.2). 
Anthracyclines become less stable as pH rises towards neutral pH and some of the analytes were 
obscured by low molecular weight endogenous serum components that survived extraction at pH 
2.5 and 4.5. So for this reason a pH of 3.5 was chosen.  
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Although there was no major difference in the resolution of separation between the 
analytes, there were some differences in peak areas however for each peak depending on the pH 
of mobile phase used. This is illustrated in Table 3.2 below. 
 
 
pH 2.5 
pH 3.5 
pH 4.5 
 
 
Figure 3.2: A 5 µg/mL sample of a combination of the five drugs in mobile phase. The same 
sample was injected and separated under the same conditions except for the pH of the mobile 
phase which was varied from 2.5 (blue) to 3.5 (red) to 4.5 (green). 
 
 
 
Table 3.2: Peak Area of each analyte at different mobile phase pH values 
 
The 5 µg/mL sample was injected in triplicate at each pH and the average peak areas are 
shown in the table above. The best response for each analyte was achieved when a pH of 3.5 is 
used in the mobile phase. 
The λmax values for the anthracyclines were at 227 and 254nm as shown in Figure 3.3. 
While it was clear that 227nm would have been best wavelength for anthracycline detection, 
interference from endogenous compounds at this wavelength was too great so the second λmax 
was used – 254nm – which proved to be successful at monitoring Dox, Epi and Dnr.  After 
elution of the anthracyclines, the detection wavelength was then changed to 234nm for optimal 
monitoring of the taxanes. 
 
 
3.4.4  Choice of SPE column 
 
An extraction column was sought that could give the greatest recoveries for both the polar 
anthracyclines and the non-polar taxanes from the complicated serum matrix. Numerous 
commercial SPE columns are available with different modes of sample clean-up. The restricted 
access material (RAM) exclusion barrier can be either chemical or physical and the surface 
Drug Peak area at pH 2.5 %RSD @ pH 2..5 Peak area at pH 3.5 %RSD @ pH 3.5 Peak area at pH 4.5 %RSD @ pH 4.5 
Dox 
Epi 
Dnr 
Doc 
Pac 
305 
666 
583 
272 
417 
1.64 
2.31 
2.89 
3.59 
2.11 
334 
666 
616 
339 
420 
2.37 
1.89 
2.33 
4.53 
2.94 
258 
634 
587 
257 
401 
4.35 
2.11 
1.74 
3.47 
2.56 
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topochemistry of the columns can be composed of a single or dual type substance. A number of 
different brands and types of extraction sorbents were tested in terms of the recovery they could 
yield for each of the analytes from human serum. A number of different types of SPE sorbents 
were tested for these drugs to see which was most suitable.  
 
 
 
Figure 3.3: UV spectra of anthracyclines and taxanes 
 
The following Phenomonex SPE cartridges (Strata-X, Strata X-C, Strata X-CW, Strata-
X-AW, Strata-C18, Strata-C18-E and Strata-SDB-L) were evaluated off-line in a vacuum 
manifold in terms of their ability to selectively retain anthracyclines and taxanes. These SPE 
cartridges were thoroughly investigated in terms of their abilty to extract both drug classes. Each 
type was evaluated at a range of different pH values from pH 2.5 to pH 10.5. Some of the SPE 
cartridges were only able to extract a single drug class - for example the Strata X-C and Strata X-
CW could only extract taxane drugs with recoveries of up to 90%. Other more promising 
cartridges such as the Strata X-AW and Strata X could extract quantities of both drug classes. 
The Strata X was the more efficient of the two with anthracycline recoveries of up to 60% and 
taxane recoveries of up to 106% 10.  
Also investigated were three types of Biotrap 500 SPE column (C8, C18 and MS). The 
SPE MS column from Biotrap was found to give the highest recoveries for all five analytes and 
so was used in the final on-line method. With the Biotrap SPE columns recovery of both 
anthracycline and taxane drugs was >85%. The Biotrap MS SPE showed the most potential of 
the three SPE columns. Despite the Strata X cartridge showing high taxane recovery, its low 
anthracycline recovery led to the choice of the Biotrap MS SPE column for sample extraction. 
 
 
3.4.5  Choice of SPE solvent 
 
Many different extraction solvents were tested including mixtures of water in acetonitrile, 
isopropanol and methanol. The amount of organic modifier added to the extraction solvent varied 
from 2-4% v/v and the solvents were tested at different pH values ranging from 3-10 adjusted 
with formic acid or ammonium hydroxide in water to obtain the required pH. Different buffers 
were also tested and these included ammonium formate, sodium phosphate and formic acid. It 
 
254nm
 
227nm
 
Typical UV spectrum of 
 
an anthracycline
 
234nm
 
Typical UV spectrum
 
 
of a taxane
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was determined based on analyte recovery of all five cancer drugs that the optimal extraction 
solvent was 30 mM ammonium formate/acetonitrile, 98/2 v/v, pH 6.8.  
The conditions and timing for loading, washing and eluting were critical and were 
optimised in terms of recovery of analytes from the serum sample. The length of extraction time 
and the extraction solvent flow rate were determined to be the most important factors. Extraction 
times were varied from 1 to 5 min at flow rates of between 1.0 – 4.0 mL/min. Optimal extraction 
conditions for both drug classes in terms of recovery were determined to be a flow rate of 2.0 
mL/min for 150 sec. It was determined that at an extraction time of 1.0 min was not sufficient at 
eluting all retained drugs from the SPE column. After 2.0 min extraction time there was still 
some target analytes adhering to the SPE column. After between 2.5 and 3.0 min it seemed that 
all injected analytes had been extracted from the SPE column onto the analytical column. At 
extraction times greater than 3.0 min no extra amounts of analytes were extracted from the SPE 
column. Sample recovery increased from 1.0 min extraction time to 2.5 min extraction time with 
no further increase after this. The flow rate of the extraction solvent was also varied. At 1.0 
mL/min it took too long for all target analytes to be washed from the SPE column. A flow rate of 
2.0 mL/min was determined to be the optimal flow rate for the extraction solvent as it was 
capable of eluting all retained drugs from the SPE column within 2.5 min. There was no 
increased analyte recovery using flow rates quicker than 2.0 ml/min.  
The final method allowed for the extraction, separation and detection of five drugs spiked 
into neat human serum (see Figure 3.4). 
 
 
 
Figure 3.4: Chromatogram showing the separation of a spiked serum sample containing all five 
drugs at 5.0 µg/mL following on-line SPE. The anthracyclines elute first in the order Dox, Epi 
and Dnr. The taxanes elute later in the order Doc and Pac. There is little or no matrix interference 
evident from the serum. 
 
 
 
 
3.5 Method validation 
 
A full validation procedure was performed on the method including intra-day and inter-day 
precision, accuracy, sensitivity, linearity and range and recovery. Stability following freeze-thaw 
cycles was also investigated. 
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3.5.1 Precision and accuracy 
 
Intra- and inter-day accuracy and precision were determined from standards prepared in serum 
over a concentration range of 0.5 µg/mL to 25 µg/mL. Precision was expressed as percentage 
relative standard deviation (%RSD). Accuracy was expressed as the ratio of the mean calculated 
concentration against the spiked concentration for each standard multiplied by 100%. For intra-
day precision and accuracy, five different standards (0.5,1.,5,10 and 25 µg/mL) were analysed in 
triplicate. Inter-day precision and accuracy were determined by analysing the standards on five 
different days in triplicate. Table 3.3 displays the data for intra- and inter-day precision and 
accuracy respectively. Intra-day precision ranged from 2.0 to 10.8 % RSD and inter-day 
precision ranged from 2.0 to 14.9 % RSD. All precision values were ≤ 15%. The accuracies 
ranged from 88.0 to 136.0% and these values compare quite well with those reported by other 
authors such as Barker 11, Ricciarello 12 and Garg et al 13. It is quite likely that these precision 
and accuracy values could be improved if automated switching was used instead of manual 
switching.  
 
 
3.5.2 Sensitivity 
 
The limit of detection (LOD) was set as the lowest concentration of the compounds (Dox, Epi, 
Dnr, Doc and Pac) that could be detected from samples in drug free serum with a signal-to-noise 
ratio of 3:1. The limit of quantification (LOQ) was defined as that concentration which had a 
signal-to-noise ratio of at least 5:1 9. LOD and LOQ values were obtained by measuring the 
signal-to-noise ratio at and nearby where target analytes eluted and by measuring the 
concentration of that analyte which was either three or five times that baseline noise. The LOD 
values were found to be 0.1 µg/mL for Epi and Dnr and 0.15 µg/mL for Dox, Doc and Pac. The 
LOQ was 0.5 µg/mL for all five compounds using 0.1 mL serum. The method is not as sensitive 
as the methods developed by either Garg 13 or Rouini et al 14 for taxane analysis with UV 
detection. The methods sensitivity is affected by the fact that both polar and non-polar drugs are 
extracted, separated and detected in the same single assay. A compromise had to be made 
between recovery and sensitivity because of the combination of drugs being studied. Most SPE 
columns are designed for either polar or non-polar drugs, not both simultaneously.  
To obtain high recoveries of all analytes the sensitivity of the method suffered. The 
current sensitivity of the method was adequate for determination of anthracyclines and taxanes 
immediately or very soon after administration of the drugs to patients but detection limits would 
need to be lower (≤ 25 ng/mL) for therapeutic drug monitoring. Replacement of the UV detector 
with a mass spectrometer would significantly lower the detection and quantitation limits for this 
purpose. Bearing this in mind, sensitivity was increased in this assay by using a larger (200 µL) 
sample loop thereby doubling the amount of sample injected. However, after repeated serum 
injections at this larger volume small blockages occurred at the top of the analytical column due 
to some excess macromolecular material in the serum surviving the extraction process. This 
increased system backpressure and affected reproducibility. Prolonging the extraction time did 
not sufficiently eliminate the blockage. 
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Table 3.3: Intra-Day and Inter-Day precision and accuracy 
 
 
3.5.3 Linearity and range 
 
Calibration curves were prepared in drug free serum spiked with stock solutions of each analyte. 
The concentration range tested was from 0.5 µg/mL to 25 µg/mL. Three external standard 
calibration curves were analysed by plotting peak area versus drug concentration. All calibration 
curves proved to be linear over the range of 0.5 µg/mL to 25 µg/mL. The regression coefficients 
(R2) values for each calibration curve were > 0.998 in all cases. 
 
 
3.5.4 Recovery 
 
Recovery is the principle criterion by which to judge whether an extraction is successful or not. 
Recovery is a percentage of the ratio of actual concentration found versus expected 
concentration. The closer the recovery is to 100% the more efficient the extraction process.  
On the one day, standards at concentrations of 1.0, 10 and 25 µg/mL were prepared three 
times for each concentration and then analysed in triplicate. The analyte peak areas obtained for 
spiked serum samples were compared to analyte peak areas obtained for spiked samples in 
  INTRA-DAY INTER-DAY 
Compound Spiked Conc. 
(µg/mL) 
Calculated Conc. 
(µg/mL) 
 
Accuracy 
% 
 
Precision 
%RSD 
 
Calculated Conc. 
(µg/mL) 
 
Accuracy 
% 
 
Precision 
%RSD 
 
 
 
 
Dox 
 
 
 
 
 
Epi 
 
 
 
 
 
Dnr 
 
 
 
 
 
Doc 
 
 
 
 
 
Pac 
 
0.5 
1.0 
5.0 
10.0 
25.0 
 
0.5 
1.0 
5.0 
10.0 
25.0 
 
0.5 
1.0 
5.0 
10.0 
25.0 
 
0.5 
1.0 
5.0 
10.0 
25.0 
 
0.5 
1.0 
5.0 
10.0 
25.0 
 
 
0.68 
1.13 
4.82 
9.74 
25.13 
 
0.66 
1.04 
4.84 
9.88 
25.08 
 
0.57 
0.96 
4.57 
10.50 
24.85 
 
0.44 
0.86 
4.80 
10.90 
25.15 
 
0.68 
1.13 
4.56 
10.04 
25.08 
 
135.6 
113.2 
96.3 
97.4 
100.5 
 
132.4 
104.4 
96.8 
98.8 
100.3 
 
114.0 
96.0 
91.4 
105.0 
99.4 
 
88.0 
86.0 
96.0 
109.0 
100.6 
 
136.0 
113.0 
91.2 
100.4 
100.3 
 
8.0 
5.5 
5.0 
3.2 
4.1 
 
7.4 
8.7 
3.9 
4.1 
2.0 
 
10.8 
7.1 
2.4 
5.0 
4.1 
 
7.0 
2.3 
5.6 
5.3 
8.0 
 
2.8 
2.4 
5.2 
2.1 
8.4 
 
0.64 
1.11 
4.33 
8.82 
21.54 
 
0.63 
0.99 
4.60 
9.72 
23.29 
 
0.55 
0.87 
4.27 
9.14 
22.66 
 
0.46 
0.92 
4.39 
9.68 
23.79 
 
0.68 
1.07 
4.47 
9.63 
24.28 
 
128.0 
111.1 
86.6 
88.2 
86.2 
 
126.4 
98.7 
92.0 
97.2 
93.2 
 
110.0 
87.0 
85.4 
91.4 
90.6 
 
92.0 
92.0 
87.8 
96.8 
95.2 
 
136.0 
107.0 
89.4 
96.3 
97.1 
 
3.9 
4.5 
5.1 
12.9 
12.6 
 
7.9 
2.0 
3.8 
8.8 
8.0 
 
10.1 
6.3 
5.9 
10.8 
10.8 
 
14.9 
6.6 
3.9 
14.3 
11.2 
 
11.8 
8.6 
5.9 
11.7 
11.2 
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mobile phase after SPE extraction. Recovery data for each drug from serum is presented in Table 
3.4. Recovery values ranged from 85.8% to 117.2%. These values compare very well with 
previously obtained recoveries in single drug class assays for taxanes of between 86 to 95% 15 
and > 90% 16 and for anthracyclines of between 80 to 102% 17 and > 80% 18. 
 
 
Compound 
 
1µg/ml 
Spiked Conc. 
 
10µg/ml 
Spiked Conc. 
 
25µg/ml 
Spiked Conc. 
 
Dox 
Epi 
Dnr 
Doc 
Pac 
 
117.2 
100.9 
101.2 
85.8 
104.6 
 
 
98.1 
102.0 
93.6 
94.0 
108.9 
 
107.8 
102.8 
110.1 
101.6 
94.1 
 
Table 3.4: Recovery data for drugs from serum (n = 3) 
 
 
3.5.5 Stability 
 
The stability of each of the five chemotherapy drugs investigated was determined following one, 
two and three freeze-thaw cycles. It is important to check the stability of samples in order to 
determine their optimal storage conditions and expiration dates, to see how many times a sample 
is stable under freeze-thaw cycles. Spiked serum samples were analysed in triplicate at three 
concentrations (1.0, 10 and 25 µg/mL). On the first day the serum samples were spiked and each 
sample extracted and analysed. The remaining samples were then frozen and analysed a further 
three times following successive freeze-thaw cycles. 
Stability data on the anthracyclines and taxanes over three freeze-thaw cycles is presented 
in Table 3.5. Cycle 0 represents a freshly prepared spiked serum sample; cycle 1 represents a 
sample injected from the remaining stock after a single freeze-thaw cycle etc. The anthracyclines 
remained quite stable after all three freeze-thaw cycles showing only a 10% decrease in signal 
response while the taxanes appeared to be less stable showing a significant 20% decrease in 
signal response by the third cycle. A 20% signal decrease is higher than a previously quoted 
signal response following freeze thaw cycles in the literature for taxanes. Grozav et al 15 and 
Mortier et al 8 both found that freeze thaw stability of taxanes fell within a 15% deviation range. 
However Mortier et al found that the stability of p‘-3-hydroxypaclitaxel in plasma suffered a 
25% degradation following freeze thaw cycles. 
 
 
 
 
3.5.6 Patient Samples 
 
Patient serum samples were obtained and analysed from patients treated with epirubicin (Epi) 
and with docetaxel (Dox) to test method performance. The samples were obtained 10 min after 
completion of administration to the patient. 
Unspiked serum samples from patients who were administered Epi (100 mg/m2) or Doc 
(75 mg/m2) were subjected to the full assay (extraction and separation) in order to test the 
method’s performance. Figure 3.5 displays overlaid chromatograms showing patient sample 
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chromatograms. The peaks correlating to Epi and Doc are evident from their retention times (6.0 
and 12.2 min respectively) which shows that the method could be applied to the analysis of 
serum samples containing these drugs (or indeed Dox, Dnr and Pac) in the concentration range 
0.5 µg/mL to 25 µg/mL. Patients may have drug levels at the lower end of this linear range in 
their system after drug administration but for therapeutic drug monitoring of patient samples the 
linear range would have to be lower as the drugs are metabolised. 
 
Compound 
 
Spiked Conc. (µg/mL) Cycle 0 Cycle 1 Cycle 2 Cycle 3 
 
 
Dox 
 
 
 
Epi 
 
 
 
Dnr 
 
 
 
Doc 
 
 
 
Pac 
 
 
1.0 
10.0 
25.0 
 
1.0 
10.0 
25.0 
 
1.0 
10.0 
25.0 
 
1.0 
10.0 
25.0 
 
1.0 
10.0 
25.0 
 
100.0 
100.0 
100.0 
 
100.0 
100.0 
100.0 
 
100.0 
100.0 
100.0 
 
100.0 
100.0 
100.0 
 
100.0 
100.0 
100.0 
 
93.7 
101.0 
93.0 
 
98.0 
93.3 
94.3 
 
99.7 
99.7 
93.7 
 
95.0 
97.7 
91.3 
 
91.3 
100.0 
89.7 
 
 
87.3 
98.3 
88.0 
 
96.3 
92.7 
94.3 
 
97.3 
101.3 
97.3 
 
80.0 
91.3 
89.0 
 
89.0 
95.7 
82.7 
 
86.3 
90.7 
87.3 
 
93.7 
83.3 
87.3 
 
94.0 
92.3 
93.0 
 
72.7 
80.7 
81.7 
 
81.8 
87.3 
81.7 
 
Table 3.5: Stability of drugs to freeze-thaw cycles (n = 3) 
 
 
 
 
 
Figure 3.5: Chromatograms of (a) blank human serum, (b) serum taken from a patient 10 min 
after administration of Doc and (c) serum taken from a patient 10 min after administration of 
Epi. Time offset between signals at 10%. 
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3.6 Conclusions 
 
In conclusion, a simple, fast, reliable on-line SPE-LC-UV method for the simultaneous 
determination of serum levels of two very important and different classes of chemotherapeutic 
drugs has been developed and validated. This is the first method reported that can extract, 
separate and detect these five drugs in a single assay. Although the method is not sensitive 
enough for therapeutic drug monitoring at low serum concentrations using UV detection, the 
method demonstrates high recoveries for all five drugs from serum, the run time is fast and there 
are negligible matrix interference effects. The on-line SPE extraction procedure offers many 
advantages over current off-line extraction procedures in terms of speed (it takes only 150 
seconds), recovery (high and reproducible) and reduction of human error. If the sensitivity of the 
method could be improved, either by injecting a larger sample volume or by incorporating a 
mass spectrometer as the mode of detection, the method could be applied as a means to ensure 
patients undergoing chemotherapy treatment with these drugs are receiving adequate 
concentrations of the drug at all times. 
 
 
 
3.7 References  
1.   Badea I, Lazăr L, Moja D, Nicolescu D, Tudose A. A HPLC method for the simultaneous 
determination of seven anthracyclines. Journal of Pharmaceutical and Biomedical Analysis, 
2005 9/1;39(1-2):305-9. 
2.  Andersen A, Warren D, Brunsvig P, Aamdal S, Kristensen G, Olsen H. High sensitivity 
assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-
performance liquid chromatography with UV detection. BMC Clinical Pharmacology 
2006;6(1):2. 
3.   Friedrichs K, Hölzel F, Jänicke F. Combination of taxanes and anthracyclines in first-line 
chemotherapy of metastatic breast cancer: An interim report. European Journal of Cancer, 
2002 9;38(13):1730-8. 
4. Li R, Dong L, Huang J. Ultra performance liquid chromatography–tandem mass 
spectrometry for the determination of epirubicin in human plasma. Analytica Chimica Acta, 
2005 8/8;546(2):167-73. 
5.  Mazuel C, Grove J, Gerin G, Keenan KP. HPLC-MS/MS determination of a peptide 
conjugate prodrug of doxorubicin, and its active metabolites, leucine-doxorubicin and 
doxorubicin, in dog and rat plasma. Journal of Pharmaceutical and Biomedical Analysis, 
2003 12/5;33(5):1093-102. 
 61
6.  Gréen H, Vretenbrant K, Norlander B, Peterson C. Measurement of paclitaxel and its 
metabolites in human plasma using liquid chromatography/ion trap mass spectrometry with 
a sonic spray ionization interface. Rapid Communications in Mass Spectrometry 
2006;20(14):2183-9. 
7.   Guo P, Ma J, Li S, Gallo JM. Determination of paclitaxel in mouse plasma and brain tissue 
by liquid chromatography–mass spectrometry. Journal of Chromatography B, 2003 
12/5;798(1):79-86. 
8.  Mortier KA, Renard V, Verstraete AG, Van Gussem A, Van Belle S, Lambert WE. 
Development and validation of a liquid Chromatography−Tandem mass spectrometry assay 
for the quantification of docetaxel and paclitaxel in human plasma and oral fluid. Anal 
Chem 2005 07/01;77(14):4677-83. 
9.    Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan 
CT, Cook CE, McDowall RD, Pittman KA, Spector S. Analytical methods validation: 
Bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 1992;81(3):309-
12. 
10. Callaghan A, Bermingham S, McMahon G. Development of an on-line clean-up method for 
extraction of two anti-cancer drugs from serum. Journal of undergraduate chemistry 
research, 2009, 8(1),8. 
11. Barker IK, Michael Crawford S, Fell AF. Determination of plasma concentrations of 
epirubicin and its metabolites by high-performance liquid chromatography during a 96-h 
infusion in cancer chemotherapy. Journal of Chromatography B, 1996 6/7;681(2):323-9. 
12. Ricciarello R, Pichini S, Pacifici R, Altieri I, Pellegrini M, Fattorossi A, Zuccaro P. 
Simultaneous determination of epirubicin, doxorubicin and their principal metabolites in 
human plasma by high-performance liquid chromatography and electrochemical detection. 
Journal of Chromatography B, 1998 4/10;707(1-2):219-25. 
13. Garg MB, Ackland SP. Simple and sensitive high-performance liquid chromatography 
method for the determination of docetaxel in human plasma or urine. Journal of 
Chromatography B, 2000 10/10;748(2):383-8. 
14. Rouini MR, Lotfolahi A, Stewart DJ, Molepo JM, Shirazi FH, Vergniol JC, Tomiak E, 
Delorme F, Vernillet L, Giguere M, Goel R. A rapid reversed phase high performance liquid 
chromatographic method for the determination of docetaxel (taxotere®) in human plasma 
using a column switching technique. J Pharm Biomed Anal 1998 9/30;17(8):1243-7. 
15. Grozav AG, Hutson TE, Zhou X, Bukowski RM, Ganapathi R, Xu Y. Rapid analysis of 
docetaxel in human plasma by tandem mass spectrometry with on-line sample extraction. J 
Pharm Biomed Anal 2004 9/21;36(1):125-31. 
 62
16.  Suno M, Ono T, Iida S, Umetsu N, Ohtaki K, Yamada T, Awaya T, Satomi M, Tasaki Y, 
Shimizu K, Matsubara K. Improved high-performance liquid chromatographic detection of 
paclitaxel in patient's plasma using solid-phase extraction, and semi-micro-bore C18 
separation and UV detection. Journal of Chromatography B, 2007 12/1;860(1):141-4. 
17.  Sottani C, Tranfo G, Bettinelli M, Faranda P, Spagnoli M, Minoia C. Trace determination of 
anthracyclines in urine: A new high-performance liquid chromatography. Rapid 
Communications in Mass Spectrometry 2004;18(20):2426-36. 
18.  Mahnik SN, Rizovski B, Fuerhacker M, Mader RM. Development of an analytical method 
for the determination of anthracyclines in hospital effluents. Chemosphere, 2006 
11;65(8):1419-25. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 63
 
Chapter 4 
 
Development of an on-line SPE-LC-MS method for the 
simultaneous determination of anthracyclines and taxanes in human 
serum 
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4.1 Introduction 
Both anthracyclines and taxanes may be used in tandem to treat certain types of cancer such as 
advanced cancers of the breast or stomach 1. Despite the fact that these drugs can be 
administered simultaneously, until now, no methods have been able to quantify both drug types 
in a single assay. The previous chapter described work carried out to develop and on-line SPE-
LC-UV method for determination of a number of drugs from both classes in a single assay. 
While the method worked well on all fronts of extracting, separating and detection, it lacked the 
necessary sensitivity for real therapeutic drug monitoring of such drugs. Detection limits were in 
the low µg/mL range, whereas ideally sensitivity in the ng/mL range is required for patient 
samples 2. Hence it was decided that a mass spectroscopic detector would be required for this 
purpose and so an on-line SPE-LC-MS method was developed for the determination of 
anthracyclines and taxanes in human serum. 
 
4.2 Scope of work 
 
The objective of this research was to develop a simple, automated, quantitative method for the 
simultaneous determination of both anthracycline and taxane drug molecules from human serum 
using an on-line SPE-LC-MS method. The method of extraction and separation used was similar 
to that used in the SPE-LC-UV method described in the previous chapter.  
The first step involved transferring the extraction and separation parts of the assay over to 
the new LC-MS instrument. This involved scaling down the analytical column and flow rate. 
Also, the type of switching valve used in this work was different to the manual valve employed 
in the UV method. The built-in internal 6-port valve could be triggered electronically by the LC 
software which enabled an improved level of automation. The development and optimisation of 
the ionisation and other MS parameters for each drug assayed proved challenging and was not 
straightforward. However, finally the overall method was developed and patient samples were 
analysed. 
 
 
4.3 Experimental 
4.3.1 Materials and reagents 
Water, acetonitrile, formic acid, ammonium formate, isopropanol (all MS grade) and human 
serum were purchased from Sigma Aldrich. Doxorubicin, epirubicin, daunorubicin, docetaxel 
and paclitaxel were all bought from Fluka Chemicals (Ireland). Patient serum samples containing 
either docetaxel or epirubicin were kindly supplied by Saint Vincent’s Hospital (Dublin). 
Ammonium formate buffer (1M) was prepared by dissolving 3.15g of ammonium formate in 50 
mL water. This buffer was used to adjust the aqueous mobile phase to pH 3.5. 
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4.3.2 Instrumentation 
 
The LC-MS system used in this work consisted of two Agilent binary 1200 (SL) pumps (one for 
the extraction solvent and one for the analytical mobile phase), a model 1200 autosampler (ALS 
SL) with a 100 µL injection loop, a thermostatted column compartment (TCCSL), an Agilent 
6410 triple quad LC-MS and an on-line Agilent 1200 degasser. A model 1100 PDA UV-Vis 
detector was coupled to the MS system to monitor the elution of the chemotherapeutic drugs 
from the analytical column during the transfer of the LC-UV method to the LC-MS. A T-piece 
and syringe pump, Agilent KD scientific (KDS 100) model were used for direct infusion. The 
system was equipped with Agilent Masshunter Workstation Software Version B01.03/04 for 
system control and data collection. A gradient LC system using an acidified water/acetonitrile 
mixture was used to separate the analytes on an Agilent Zorbax column (50 x 2.1mm i.d, particle 
size 3.5µm) packed with XDB C18 material. The extraction column used was a Biotrap 500 MS 
SPE column (20 x 4mm i.d) packed with a hydrophobic polymer material and was coupled to the 
LC system via a built-in six port switching valve (see Figure 4.1).  
 
 
 
 
 
Figure 4.1: Schematic representation of the 6-port switching valve used for on-line sample 
extraction and the resulting flow paths in the two valve positions. 
 
4.3.3 Preparation of stock and standard solutions 
 
Stock solutions of Epi, Dox, Dnr, Doc and Pac, all 2 mg/mL, were weighed in a glove box and 
prepared by dissolving the compound in acidified water (adjusted to pH 3.5 with formic acid) for 
the anthracyclines and in neat methanol for the taxanes. All stock and standard solutions were 
stored in the refrigerator and protected from light. Standard solutions of the drugs were prepared 
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(250 µg/mL) monthly by dilution with appropriate solution. Fresh working standard solutions 
were prepared daily by dilution of the standard solution(s) in the aqueous mobile phase to the 
concentrations required. 
 
4.3.4 Preparation of serum samples 
The 2 mg/mL stock anthracyclines and taxanes were dissolved in thawed drug free serum 
samples to obtain the required concentrations in undiluted serum. The samples were spiked prior 
to analysis and were kept cool at 40C in the autosampler.  
Patient venous blood samples were obtained from patients undergoing chemotherapy in 
St. Vincent’s Hospital, Dublin, Ireland by informed consent at 10 min after administration. The 
whole blood samples were immediately centrifuged to yield serum. The samples were kept 
frozen at -20 0C until analysed. 
 
4.3.5 Sample extraction and clean-up procedure 
 
Sample clean-up was performed on-line using the same Biotrap 500 MS SPE column as in the 
previous assay. The 10 µL sample (standard solution or human serum) was injected by the 
autosampler while the valve was set to position A (see Figure 4.1). In this configuration, the 
extraction solvent (30 mM ammonium formate/acetonitrile, 98/2 v/v, pH 6.8) flowing at 2.0 
mL/min for 2.0 min, picked up the injected sample forcing it onto the SPE column and washed 
any proteinaceous material from the serum to waste leaving the drugs retained on the extraction 
column. The analytical mobile phase was rinsing the analytical column during this time. The 
valve was then switched to position B where the analytical mobile phase back-washed the SPE 
column flushing the retained drugs onto the analytical column where they were separated and 
detected. The extraction solvent then flowed directly to waste. The valve was then switched back 
to position A where the extraction solvent washed the SPE column removing any remaining 
proteinaceous material still on the SPE column readying the system for the next sample injection.  
 
4.3.6 Chromatographic conditions 
 
The gradient programme was set up as shown in Table 4.1. The extraction solvent was composed 
of 30 mM ammonium formate in water/acetonitrile (98/2 v/v), pH 6.8. Mobile phase A was 
composed of 0.1% formic acid in water/acetonitrile (90/10 v/v), pH 3.5 with ammonium formate. 
Mobile phase B was composed of 0.1% formic acid in acetonitrile/water (90/10 v/v).  
After each serum sample injected the SPE column had to be washed with a high 
percentage organic solvent to remove any retained sample. An acetonitrile/water (90/10 v/v) 
mixture was passed through the SPE column for 4.0 min to clean the SPE column prior to the 
next sample injection. This washing step was incorporated into the method.  
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Table 4.1: Extraction and analytical solvent gradient timetable  
 
4.3.7 Mass spectrometric conditions 
Different time segments needed to be implemented in the method because the anthracyclines and 
taxanes were optimally ionised under different conditions. The three anthracyclines eluted first in 
the same order as they did in the LC-UV method and their ionisation conditions were more 
gentle than those needed for the taxanes. The gas temperature, fragmentor voltage and collision 
energies were different depending on which drug class was eluting. The first time segment 
(Segment 1) was set up with the ionisation conditions for anthracyclines, the second (Segment 2) 
for the taxanes. For the third time segment (Segment 3), ionisation conditions were reverted back 
to those used in the first time segment so that all of the conditions were ready for the next sample 
injection. The ESI (+) mode MS conditions (time segments and source conditions) were set up as 
described in Table 4.2. 
 
Time 
Segments 
Start 
time 
(min) 
Scan type Valve 
(to) 
Delta 
EMV(+) 
Delta 
EMV 
(-) 
Transitions Gas Temp 
(0C) 
Collision 
energy 
Fragmentor 
voltage 
1 
 
2 
 
3 
 
0.0 
 
8.5 
 
16.0 
MRM 
 
MRM 
 
MRM 
MS 
 
MS 
 
MS 
400 
 
400 
 
400 
0 
 
0 
 
0 
544  526 +397 
and 528  321 
 
846  565 +320 
and 892  607 + 
324 
544  526 +397 
and 528  321 
300 
 
350 
 
300 
10 
 
25 
 
10 
80 
 
180 
 
80 
Table 4.2: Time segment conditions for each drug class 
 
 
Mass spectral conditions that remained the same throughout the run were as follows: 
 
Gas flow: 10 L/min 
Nebuliser: 50psi 
Capillary (+): 4000 
Time (min) Extraction solvent 
(%B) 
Extraction flow 
(mL/min) 
Analytical solvent 
(%B) 
Analytical flow 
(mL/min) 
Valve 
position 
0.00 
2.00 
2.01 
10.00 
10.10 
12.00 
16.00 
17.00 
20.00 
0 
0 
0 
0 
100 
100 
100 
0 
0 
2.0 
2.0 
0.3 
0.3 
2.0 
2.0 
2.0 
2.0 
2.0 
10 
10 
10 
75 
75 
75 
75 
10 
10 
0.3 
0.3 
0.3 
0.3 
0.3 
0.3 
0.3 
0.3 
0.3 
A 
A 
B 
B 
A 
A 
A 
A 
A 
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Capillary (-): 4000 
 
4.3.8 Calibration 
Calibration curves were prepared in drug-free serum spiked with stock solutions of each analyte. 
The concentration range tested was between 2.0 ng/mL and 500 ng/mL. Standards were prepared 
at concentrations of 0, 2.0, 5, 10, 50, 100 and 500 ng/mL in water/acetonitrile (90/10 v/v). 
Calibration curves were determined by plotting peak area versus spiked drug concentrations.  
 
4.3.9 Method validation 
 
A full validation procedure was planned for the method including intra-day precision 
(repeatability) and inter-day precision (intermediate precision), accuracy, sensitivity (LOD and 
LOQ), linearity and range and recovery according to accepted guidelines 3. Some further 
parameters were also monitored such as stability following freeze-thaw cycles 4.  
 
 
4.4 Results and discussion 
4.4.1 Method development 
 
A method that could extract, separate and detect both anthracyclines and taxanes in a single 
assay had been developed using a UV detector but required transfer over to a different 
instrument with a mass spectrometric detector. The extraction parameters required further 
changes on the new instrument and separation conditions were modified due to the reduced 
dimensions of the analytical column used. The ionisation conditions and fragmentation patterns 
of the chemotherapeutic drugs had to be determined in a logical format so that the best sensitivity 
could be achieved by tandem MS. 
 
 
4.4.2 Extraction conditions 
 
4.4.2.1. SPE cartridge 
 
There was no change to the SPE column or its dimensions in the method transfer. The SPE 
protocol was essentially the same prior to the LC-MS method as it was when used prior to the 
LC-UV method. The high extraction flow rate of 2.0 mL/min determined to be the optimal 
extraction solvent flow in terms of recovery was also suitable following method transfer.  
 
4.4.2.2. Extraction solvent 
 
There were no changes to the composition of the extraction solvent used to extract the 
chemotherapy agents, but a cleaning step was introduced so as to rinse the SPE column of any 
adhering serum components following an injection. For 4 min after a run, once all the drugs had 
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been back-washed off the SPE column onto the analytical column, the SPE column was rinsed 
with a high percentage organic solvent (acetonitrile/water 90:10 v/v). The other important 
change that was implemented was a 2.0 min extraction time was used in the MS method (as 
opposed to 2.5 min) because of the fully automated SPE protocol with 6-port column switching.  
To perform on-line SPE on the Agilent 1200 system, two Agilent 1200 binary pump were 
needed, one to pump the analytical mobile phase and the other to pump the extraction mobile 
phase. The original LC valve configuration had to be completely changed to accommodate the 
on-line extraction. A built-in 6-port valve was used to extract and separate the drugs. A 
schematic of the switching valves is shown in Figure 4.1 above. 
 
 
4.4.3 Separation conditions 
 
4.4.3.1. LC column 
 
A scaled-down version of the Agilent Zorbax XDB (150 x 4.6mm i.d, particle size 5µm) column 
used in the LC-UV method was used to separate the target analytes in the MS method. The 
downsized column had the dimensions (50 x 2.1mm i.d. particle size 3.5µm). It was assumed 
that this column would be capable of separating the five chemotherapy drugs sufficiently when 
used at a lower flow rate and by scaling the gradient appropriately. This type of column already 
proved appropriate for separating all drugs including the epimers; Dox and Epi which were well 
resolved. If the Agilent Zorbax XDB column used in the UV method had been used here in the 
MS method, the pump would have had to deliver 1.0 mL/min to maintain the same separation as 
before. At this high flow rate it would have been necessary to split the flow before entering the 
MS detector. This setup would also have resulted in unnecessary wastage of solvent.  
 
4.4.3.2. Analytical mobile phase and UV detection 
 
The same analytical mobile phase that was used in the UV method was used here in the MS 
method and it proved to be very effective in separating the five drugs. The pH stayed the same 
(pH 3.5) as it was determined from the UV method that the anthracyclines were most stable at 
this pH and there was good resolution of all analytes at this pH. A PDA UV detector was used in 
series with the MS initially and it was very useful during initial method development to ensure 
that all drugs were being well extracted and well separated. It provided reassurance during the 
method transfer process.  
Once each of the five drugs were optimised in terms of finding their optimal ionisation 
conditions, the analytical column was coupled to the system so that the gradient for their 
separation could be optimised and the time segments for changing the mass spectrometric 
conditions for analysis of the different drug types determined. 
Many of the conditions employed in the LC-UV method were used as a starting point for 
the LC-MS method. The gradient conditions did need to be changed however, as did the flow 
rate through the narrow bore column. A useful approximation when converting flow rates from 
4.6 mm i.d. at 1.0 mL/min to lower dimension columns is: 
 
Flow = (new column i.d. / old column i.d.)2 
Example:  Flow = (2.1 / 4.6)2 = 208 µL/min 
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This relationship can be used to estimate the flow rate required for an equivalent separation on a 
downscaled column. A range of flow rates from between 0.1 and 0.3 mL/min were evaluated. It 
was determined that the optimal flow rate in terms of separation and speed was obtained at 0.3 
mL/min.  
Figure 4.2 below shows the separation of a 0.25 µg/mL mixture of all five drug 
compounds dissolved in mobile phase, injected onto the Zorbax XDB (50 x 2.1mm i.d, particle 
size 3.5µm) column and separated using the gradient shown in Table 4.1. It can be seen that all 
drugs are well resolved from one another. Although closely eluting, the epimers Dox and Epi can 
also be easily distinguished from one another (and from any other closely eluting compound) by 
examining their unique fragmentation patterns discussed in section 4.4.4.2.  
 
 
 
Figure 4.2: A total ion current (TIC) scan of the separation of a mixture of all five drugs (each at 
0.25 µg/mL) prepared in mobile phase  
 
 
4.4.4 Mass spectrometric conditions 
 
There are a number of steps to follow when developing a method for the determination of drugs 
in biofluids using an MS detector. Different drugs have different ionisation properties so in order 
to determine their optimum ionisation conditions correctly these steps have to be followed.   
Initial work on the development of the MS part of the method involved directly infusing a 
small quantity of a single chemotherapeutic drug prepared in mobile phase (MS grade) to 
determine its precursor ion, its optimum conditions for fragmentation (fragmenter voltage), to 
determine its product (daughter) ions and to determine its optimum collision energy and gas 
temperature. This process was repeated for each of the individual drugs tested (Dox, Epi, Dnr, 
Doc and Pac). See Table 4.3 for the final ionisation conditions. 
Once these had all been accurately determined it was prudent to determine whether there 
were any ion enhancement or suppression effects in the sample matrix. 
 
4.4.4.1. Precursor ion scan 
 
A single chemotherapeutic drug agent was made up in mobile phase at a concentration of 0.5 
µg/mL (very concentrated for MS analysis so that the precursor (parent) mass ion could be easily 
established) and this sample was then infused directly from the autosampler to the mass 
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spectrometer where a TIC scan was run in order to establish the predominant precursor ion. The 
range was set so that it bracketed the molecular weight of the compound under analysis. The 
range used in this work was from m/z 100 to 1000. Once a large peak was seen at the expected 
m/z value (protonated, sodiated or potassiated adduct), this was deemed to be the precursor ion.  
 
4.4.4.2. Optimising fragmentation voltages for precursor ions 
 
Once the precursor ion had been established the next step was to determine the optimum 
fragmentation conditions for that precursor ion. The mass spectrometer was programmed to 
perform an MS selected ion monitoring (SIM) scan which detects only the selected precursor ion 
so that the optimum fragmentor voltage for that ion could be determined. These SIM scans were 
done in series where the fragmentor voltage was varied over a range of 0 to 300V. Initially tested 
in large fragmentor voltage increments of 40V, when the approximate optimum fragmentor 
voltage was known (between 70 and 90V and between 170 and 190V for anthracyclines and 
taxanes respectively), the increments were lowered to get a more accurate fragmentor voltage for 
each drug analysed (80 and 180V for anthracyclines and taxanes respectively). 
The taxanes required higher fragmentation voltages compared to the anthracyclines.  This 
was expected as taxanes are more lipophilic and are quite difficult to ionise unless high voltages 
are used. Anthracyclines, on the other hand are quite fragile molecules with stability issues 
(anthracyclines are very sensitive to light and pH) and hence needed lower voltages for 
ionisation to occur. There is a sugar moiety present in all anthracycline molecules and this 
moiety easily falls off at high voltages and temperatures so it was important to have strong 
enough conditions to enable efficient ionisation but not so strong as to allow in-source 
fragmentation. 
 
4.4.4.3. Product ion scan 
 
When the optimum fragmentor voltage for that drug had been established based on ion 
sensitivity, a product ion scan was carried out in order to obtain the product (daughter) ions of 
that selected precursor ion. The product ion scan test worked by firstly isolating and then 
fragmenting the chosen precursor ion with varying collision energy values. This was achieved in 
a similar fashion to the way the precursor fragmentor voltage was acquired but the collision 
energy range was much lower (0 to 80V). The product ions were determined by analysing the 
fragments produced on collision and again determining which were predominant and specific for 
the precursor ion under examination. See Figure 4.3 (A-E) for examples of precursor and product 
ion scans for each chemotherapeutic drug tested during direct infusion method development 
experiments. 
Figure 4.3 shows a typical precursor ion scan and a product ion scan for each of the five 
drugs analysed in this work. This was an important step in the method development stage of this 
on-line SPE-LC-MS method.  
It can be seen from Figures 4.3(A) and 4.3(B) that the epimers Dox and Epi produce 
different product ions in the collision cell. Epi produced products ions at m/z 397 and 526 
whereas Dox only has a product ion of m/z 397. It would have been impossible to distinguish 
between them in an MRM scan if their product ions were the same but this difference in their 
fragmentation patterns allowed for unambiguous identification. Hence, m/z 397 was used as the 
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product ion for Dox identification and m/z 526 was used as the product ion for Epi identification. 
The product ion m/z 544 corresponds to the [M+H+] adduct of both Dox and Epi. 
 
 
Figure 4.3 (A): MRM scan showing the precursor ion and product ion [M+H+] of Dox 
 
 
Figure 4.3 (B): MRM scan showing the precursor ion and product ions [M+H+] of Epi 
 
Figure 4.3 (C): MRM scan showing the precursor ion and product ion [M+H+] of Dnr 
 
 
Figure 4.3 (D): MRM scan showing the precursor ion and product ions [M+K+] of Doc 
 
Precursor Ion Product Ions 
Precursor Ion Product Ion 
Precursor Ion 
Product Ions 
Precursor Ion 
Product Ion 
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Figure 4.3 (E): MRM scan showing the precursor ion and product ions [M+K+] of Pac 
 
 
Figure 4.3 (C) shows the precursor and product ions for Dnr. The protonated precursor 
ion for Dnr was found at m/z 528 with the major product ion determined to be m/z 321.   
It is evident from Figures 4.3(D) and 4.3(E) that Doc and Pac are not easy to ionise even 
with high voltages. The intensities of the main precursor ions at 846 and 892 respectively (both 
K+ adduct ions) are relatively low compared with the background ions. However, the isolation 
step prior to fragmentation aids sensitivity for tandem MS. Doc produced two major product ions 
at m/z 565 and 328. Pac also produced two major product ions at m/z 607 and 324. Both products 
ions were easily identified in every separation. 
These fragmentation patterns can also be described molecularly. Dox has a product ion at 
m/z 397; therefore the fragmented piece has a molecular mass of 147. This can be explained by 
the loss of the sugar moiety and a hydroxyl group. Similarly, Epi has a product ion at m/z 526 
which would result in the loss of a water molecule from the precursor ion. Dnr transition is from 
m/z 528 to 381 which suggests a fragmented piece with a mass of 147 could be explained by the 
loss of the sugar moiety and a hydroxyl group. Doc and Pac have transitions of m/z 846 to 526 
and m/z 892 to 607 respectively. These can be explained by the cleavage of the large side chains 
at C15 position of the 10 membered carbon ring. The side chain on Doc has a molecular mass of 
280 which explains the transitions of m/z 846 to 526 and the side chain on Pac has a molecular 
mass of 284 which explains the transitions of m/z 892 to 607. 
 
4.4.4.4. Optimising collision energy conditions for product ions 
 
Repeated multiple reaction monitoring (MRM) scans which detected the MS/MS transitions 
were carried out in order to obtain the optimum collision energy for fragmentation of a particular 
drug to a particular product (daughter) ion. Unlike the product ion scan protocol, in this case 
collision energy was raised in increments of 5V (from 0 to 5 to 10 etc…) so that a more accurate 
collision energy could be established. The collision energy that gave the most intense peak for 
the chosen product (daughter) ion was deemed to be the optimum value. 
The taxane product ions required higher collision voltages compared to the anthracycline 
ones as taxanes are more difficult to ionise and it was predicted that their product ions would 
behave in a similar manner. The collision energy, fragmentor voltage and gas temperature were 
all significantly higher for taxane analysis showing that it was much harder to fragment the 
larger molecular weight molecules.  
The sugar moiety that often fragments from anthracycline molecules can be observed in 
Figure 4.3 above (the product ion with an m/z of 130). This molecular weight corresponds 
Precursor Ion 
Product Ions 
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exactly to the base sugar moiety present in many anthracycline drugs. The gas temperature had to 
be lowered to 300 0C for the anthracyclines because they were being broken down at the higher 
temperature before the precursor ions could be established. The final product ions of choice for 
Dox, Epi and Dnr respectively were at m/z 397, 526 and 321 (see Figure 4.4). 
In Figure 4.4 the first scan is of a TIC MRM scan showing the separation of each of the 
five chemotherapy drugs analysed. Directly below it (A) shows the transition from 544 to 397 
shared by both Dox and Epi ((A) is the same as (C) transition from 544 to 397 as it is shared by 
both Dox and Epi). Transition (B) is from 544 to 526, related only to Epi and it can be seen from 
figure 4.4 that is directly below the Epi peak in the TIC MRM. Transition (D) is from 528 and 
321 which correlates to Dnr. Transitions (E and F) are from 892 to 324 and 607 respectively, 
these transitions are from Pac and finally the transitions from 846 to 320 and 565 respectively are 
related to Doc and it can be seen from the figure that they are directly under the Doc signal in the 
TIC MRM. 
 
 
Figure 4.4: Shows an MS scan of the five separated drug compounds and the resultant MS2 
(product ion scan) for each drug under the optimal experimental conditions. 
4.4.4.5. Gas temperature 
An optimum gas temperature within the ionisation source had to be established for each drug. 
For fragile compounds, it may be appropriate to keep this low while raising it can improve LC 
DOX 
EPI 
DNR 
DOC PAC 
PAC 
PAC 
DOC 
DOC 
EPI 
DNR 
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solvent evaporation and the ionisation process. The optimum gas temperature for the 
anthracyclines (300 oC) was found to be slightly lower than the gas temperature required for the 
taxanes 350 oC. This is because the fragile sugar moiety could easily break off the anthracycline 
structure. The final conditions used in terms of collision energies, fragmentation volatages, gas 
temperatures and precursor and product ions is shown in Table 4.3. 
 
Compound Precursor 
 ion 
Product 
 ion 
Collision  
energy 
Fragmentor 
 voltage 
Gas temp 
 (0C) 
Dox 
Epi 
Dnr 
Doc 
Pac 
543/[M+H+] 544 
543/[M+H+] 544 
527/[M+H+] 528 
808/[M+K+] 846 
854/[M+K+] 892 
397 
526 + 397 
321 
565 + 320 
607 + 324 
10 
10 
10 
25 
25 
80 
80 
80 
180 
180 
300 
300 
300 
350 
350 
 
Table 4.3: Optimum positive mode ESI conditions for each target analyte 
 
4.4.4.6. Ion enhancement issues 
 
Biological matrices such as plasma, serum and urine have been known to cause ion suppression 
or enhancement effects in mass spectrometric experiments. The main cause of ion suppression 
with ESI-MS is a change in the spray droplet solution properties caused by the presence of non-
volatile or less volatile solutes. Non-volatile materials (endogenous serum components) cause a 
change in the efficiency of droplet formation which can affect the amount of charged ion in the 
gas phase that will reach the detector 5 To test for such effects, a direct infusion experiment 6 was 
performed to see what effect (if any) the serum matrix was having on an MRM scan. An aliquot 
of a single drug sample in serum had to be directly infused into the MS chamber to determine 
what effect, if any, the sample matrix had on the MRM scan for that particular drug.  
An aliquot of human serum (the sample matrix used) was injected from the autosampler 
going directly into the MS. A T-piece was put in place before the MS chamber so that an aliquot 
of a single chemotherapy agent used in the separation (e.g. Dox) could be directly infused (see 
Figure 4.5) to mix with the serum just prior to the MS when required. 
 
 
 
 
LC pump 
Autosampler LC column 
ESI-MS 
0.3 mL/min 
Syringe pump 
10 µL/min T-Piece 
 
 
Figure 4.5: Schematic representation of experimental set-up to test for ion enhancement or 
suppression effects 
  
The matrix profile should remain relatively constant after an initial ‘solvent front’. A 
large dip in the matrix profile at any point after the ‘solvent front’ indicates that there is an ion 
suppression effect at that point; a large increase in the matrix profile at any point after the 
‘solvent front’ indicates that there is an ion enhancement effect at that point. Ion suppression 
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would result in an unexpectedly low concentration of analyte in the matrix sample compared to 
the sample in mobile phase and vice versa for ion enhancement. This experiment was carried out 
for all five drugs being studied and an ion enhancement effect was found only for Dnr (see 
Figure 4.6). No ion suppression effects were found.   
 
 
 
Figure 4.6: MRM scan of a mixture of the five drugs prepared in mobile phase (red trace) 
overlaid on a mixture of the five drugs prepared in serum (blue trace). It is clear that the peak for 
Dnr is higher than it should be in the serum matrix. 
 
 
It can be seen from Figure 4.6 that each of the five drugs are well separated from each 
other but that the concentration of Dnr in the serum sample appears to be about twice that of Dnr 
in the mobile phase sample even though both mixtures were made up to the same concentration 
of 0.25 µg/mL. Many modifications were made to the solvent gradient to see if the ion 
enhancement of Dnr could be avoided but no gradient could reduce this effect.  
 
 
 
 
4.5 Method Validation 
 
A full validation procedure was planned for the method according to the guidelines in Shah et al3 
including intra-day and inter-day precision, accuracy, sensitivity, linearity and range and 
recovery. Stability following freeze-thaw cycles was also investigated. 
 
 
4.5.1 Precision and accuracy 
 
Intra- and inter-day accuracy and precision were to be determined from standards prepared in 
serum over a concentration range of 2.0 ng/mL to 500 ng/mL. Precision would be expressed as a 
(%RSD) and accuracy would be expressed as the ratio of the mean calculated concentration 
against the spiked concentration for each standard multiplied by 100% in the same way as 
calculated in chapter 3. Intra day precision and accuracy was to be determined by preparing 
seven different standards (0, 2.0, 5, 10, 50, 100 and 500 ng/mL) and analysing in triplicate.  
DOX 
EPI 
DNR 
DOC PAC 
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A problem occurred within the SPE-LC-MS system each time this method validation step 
was attempted. There was a gradual increase in system backpressure with every injected serum 
sample. Initially the pressure increase was minimal (1 or 2 Bar increase per injection) and did not 
affect system operation but with more spiked serum samples injected the pressure increase 
became more pronounced. Eventually this backpressure increase caused distortions in analyte 
retention time and finally caused the system to shut down because system pressure limits had 
been reached. Most likely there was a problem with the sample clean-up stage, some serum 
components must have survived the extraction step and were being flushed onto the head of the 
analytical column where it gradually built up causing the blockage and retention time shift. 
Initial pressure on the column before validation was ~90 Bar, when the pump was restarted the 
pressure had risen by almost 100 Bar to ~190 Bar.  
The theory that something was surviving SPE extraction seemed to be confirmed when 
the head of the analytical column used in this validation attempt was cleaned before injecting 
another serum sample onto the cleaned column. The top end of the analytical column was 
screwed off and sonnicated for 45 min before being tightly reattached. The column was then put 
back into the LC-MS setup and a serum sample injected through it. The pressure through the 
analytical column had reverted back to about 100 Bar. Column performance after this had 
unfortunately been changed with a retention shift for all analytes. This problem occurred even 
after extensive troubleshooting and the purchase of two more new analytical columns and a new 
extraction column.  
 
 
4.5.2 Sensitivity 
 
The LOD and LOQ were defined as the lowest concentration of the five target analytes that 
could be detected by the MS in serum samples. The LOD was set at a concentration that gave a 
signal to noise ratio of 3:1. The LOQ was set at a concentration that gave a signal to noise ratio 
of 5:1. These values were obtained by determining the level of background noise at and nearby 
where each target analyte eluted and determining the concentration of that drug that gave a signal 
to noise ratio of at least 3:1 or 5:1 for LOD and LOQ respectively. LOD values were 1.0, 1.0, 
1.5, 1.0 and 1.0 ng/mL for Dox, Epi, Dnr, Doc and Pac respectively. The LOQ for each drug was 
determined to be 2.0 ng/mL. These values compare very well with Yang 7 and Alexander 8 et al 
who used tandem MS in the determination of either anthracyclines (Yang) or taxanes 
(Alexander) individually.. The limiting factor in determining the LOQ was determining the 
precursor ions of Dox and Epi. The transition from 544 to 526 is unique to Epi and is the only 
way to distinguish between the two epimers. At concentrations lower than 2.0 ng/mL this 
transition was not observed. 
 
 
4.5.3 Linearity and range 
 
Linearity and range was determined by running calibration curves. Calibration curves were 
prepared in drug free serum spiked with stock solutions of each analyte at concentrations in the 
range of 2.0 to 500 ng/mL. All calibration curves proved to be linear over the tested 
concentration range. The regression coefficients (R2) values for each calibration curve were 
>0.99 in all cases. A single calibration curve could be run over the concentration range without 
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the backpressure increasing substantially by injecting each sample individually. There was still a 
backpressure increase but it was less dramatic and not so severe when only seven serum samples 
were injected. 
 
 
4.5.4 Recovery 
 
Analyte recovery was determined in the same way as it was in the LC-UV method described in 
chapter 3. On the same day, standards at concentrations of 5, 100 and 500 ng/mL were prepared 
three times for each concentration and then analysed in triplicate. The analyte peak areas 
obtained for spiked serum samples were compared to analyte peak areas obtained for spiked 
samples in mobile phase after SPE extraction. Recovery of Dox, Epi, Doc and Pac were very 
good ranging from 95 to 113% and compared well with work done by Arnold 9 and Parise 10 et al 
who obtained high recovery in their methods to extract anthracyclines (Arnold) and taxanes 
(Parise) from complex biological matrices. Recovery of Dnr was about twice that of every other 
analyte investigated. This can be explained by the ion enhancement effect as described in Figure 
4.6. See Table 4.4 for recovery data. 
 
 
Compound 
 
5 ng/mL 
Spiked Conc. 
 
100 ng/ml 
Spiked Conc. 
 
500 ng/ml 
Spiked Conc. 
 
Dox 
Epi 
Dnr 
Doc 
Pac 
 
105.4 
114.7 
210.5 
98.3 
94.6 
 
 
110.6 
108.1 
218.2 
104.1 
98.3 
 
102.3 
112.7 
205.3 
97.6 
94.9 
 
Table 4.4: Recovery data for the five drugs in human serum 
 
 
4.5.5 Stability 
 
The stability of each drug was to be determined by freeze-thaw cycles as it was in the LC-UV 
method. The concentrations of the drugs that were to be analysed under freeze-thaw cycles were 
5, 100 and 500 ng/mL. These samples were run once and frozen (samples ran on the first day of 
the ‘precision and accuracy’ testing. After precision and accuracy tests failed (blocked column) 
the column performance had diminished so stability testing was not completed. 
 
 
4.5.6 Patient samples 
 
Patient samples containing both Epi and Doc were kindly supplied from St. Vincents Hospital, 
Dublin. For the same reasons as those explained under the stability section of this validation 
protocol, despite repeated attempts at preparation and analysis, the patient samples were never 
fully analysed. Column performance had diminished and due to time constraints the assay was 
not able to be tested fully with clinical samples. 
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4.6 Conclusions 
 
An on-line SPE-LC-MS method was developed that was capable of quantifying two very 
different types of chemotherapeutic agents in a single assay. The developed method is capable of 
extracting, separating and detecting the five chemotherapy drugs of interest in a rapid (20 min) 
assay. The detection limits of this method were an order of magnitude lower than the limits 
obtained with the UV method. The LOQ was determined to be 2.0 ng/mL. Rates of detection this 
low are suitable for therapeutic drug monitoring. Detection limits could have been lower if either 
Dox or Epi were omitted as quantitation of both the epimers Dox and Epi in the one assay was 
challenging. A patient would never be given a combination of these two drugs during therapy 
however so one of these anthracyclines could be left out in order to get lower detection limits for 
the other epimer. 
There appeared to be a problem with the extraction protocol when coupled to the LC-MS 
in this method which resulted in a pressure increase over time with multiple injections. 
Endogenous compounds in the serum sample seemed to survive the extraction wash and caused a 
blockage at the analytical column. This problem may possibly be overcome by increasing the 
length of SPE rinses or by further investigating the column switching timetable. Extensive 
troubleshooting carried out at the time of the problem did not fix the pressure issue. A pre-
column was placed in front of the analytical column to see if it could ‘catch’ whatever was 
causing the blockage but it seemed to be too porous because the pressure problem persisted. One 
possible solution that could be tried in the future would be to change the analytical column to 
one with similar dimensions to the column used in the LC-UV method (Zorbax XDB (150 x 4.6 
mm, 5 µm i.d.)) and use the same gradient and flow rate as that used in the LC-UV method. As 
1.0 mL/min would be too fast a flow rate to enter the MS, the flow could be split before entering 
the MS chamber so that a slower flow would go to the MS. A second option for avoiding the 
pressure problem would be to change the type of SPE column but this would obviously involve a 
lot more method development work. 
Although the SPE-LC-MS method could not be fully validated due to pressure problems, 
initial data was very good.  Accuracy and precision values could not be evaluated but LOD, LOQ 
and recovery results were excellent. Also, the overall assay was found to be easy due to being 
fully automated, fast since it took only 20 min for extraction, separation and detection and less 
prone to error due to removing labour-intensive sample pretreatment steps. Finally, this is the 
first time to the author’s knowledge that one assay can determine both classes of 
chemotherapeutic drug simultaneously. 
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Chapter 5 
 
Overall conclusions and further work 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 82
 
5.1 Overall conclusions and further work 
 
Both anthracyclines and taxanes may be used in tandem to treat certain types of cancer such as 
This thesis has discussed the development and validation of methodology for the determination 
of the anthracycline and taxane classes of chemotherapeutic drugs. The aim was to create 
reliable, efficient and fast methods for analysis of these drugs in human serum and to apply, 
where possible, novel, fast extraction and detection techniques in the determination of these 
drugs. The main research objectives at the outset were: 
 
• To develop and validate an on-line SPE-LC-UV method for the simultaneous 
determination of anthracyclines and taxanes in human serum 
• To develop and validate an on-line SPE-LC-MS/MS method for the simultaneous 
determination of anthracyclines and taxanes in human serum 
 
Most of these objectives were achieved. In chapter 3, the first reported SPE-LC-UV method for 
the determination of anthracyclines and taxanes in human serum has been described. The method 
was successful in that it could quantify both drug types in a quick reliable manner. Analyte 
recovery from human serum was high (86 to 117 %) within the concentration range tested. The 
method also has the potential for high sample throughput. The only drawback of this method was 
its sensitivity. With detection limits only in the low µg/mL range, therapeutic drug monitoring of 
these drugs would not be an even though Epi and Doc could be seen in patient samples taken 
directly after administration. 
The SPE-LC-UV method was developed, optimised and fully validated. A manuscript 
describing this work has been submitted to the Journal of Separation Science and is currently 
under review.  
The above method was then transferred to a system with a mass spectrometric detector 
and this work was described in chapter 4. Sensitivity with this method was about three orders of 
magnitude lower (low ng/mL) in serum than that achieved when the UV detector was used. 
Detection limits with the MS detector where at about 2.0 ng/mL for drug samples in serum. 
Therapeutic drug monitoring of both drug class would be easily achieved at this level of 
detection. This method also offered more reliable identification of parent drugs and fragment 
ions and could be used in the future for monitoring metabolites in pharmacokinetic and 
pharmacodynamic studies.  
Unfortunately, this method could not be validated due to a pressure increase on the 
analytical column after repeated serum injections. Exactly what was causing this pressure 
increase could not be determined in time before this research was completed. It seemed as if a 
component of the serum was surviving the extraction process and blocking the top of the 
analytical column. However, during pre-validation work on this method this blockage did not 
occur when numerous serum samples were passed through the system. 
Future work would start with full validation of the SPE-LC-MS method and evaluation of 
clinical patient samples for therapeutic drug monitoring. 
 It would be interesting to investigate some newer extraction approaches for the 
anthracyclines and taxanes such as magnetic beads. A recent preliminary study in the group 
yielded very promising results for simultaneous extraction of both drug classes in a very short 
time with high recoveries1. Another approach could be the use of 96 well plates for high 
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throughput supported liquid membrane extraction of the compounds. As the drugs have been 
previously isolated successfully from serum using liquid-liquid extraction, this protocol should 
be effective.   
It would also be worthwhile to look at other separation techniques for the anthracyclines 
and taxanes, in particular capillary electrophoresis. This would have the advantages of smaller 
sample volume requirements, fewer issues with blockages of the capillary from biofluids and less 
need for organic solvents.  
 Ultimately, these methods and their speed and automation are important in the cancer 
treatment arena since their availability offers more possibilities to clinicians in terms of 
therapeutic drug monitoring, pharmacokinetic studies, clinical trials and indeed, individualisation 
of patient dosage. While there is still much to do in the area of cancer research, any new 
analytical research, such as that described in this thesis, will add to the knowledge already there 
and hopefully will benefit patients.  
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Appendix 1:  Publications 
 
1. Published paper  
 
• Callaghan A, Bermingham S and McMahon G. Development of an on-line clean-up 
method for extraction of two anti-cancer drugs from serum, Journal of Undergraduate 
Chemistry Research, 2008, 7(1), 152 
 
2. Submitted papers 
 
• Bermingham S, O’Connor R, Regan F and McMahon G. Simultaneous determination of 
anthracyclines and taxanes in human serum using on-line sample extraction coupled to 
high performance liquid chromatography with UV detection. Submitted to the Journal of 
Separation Science, currently awaiting review. 
 
• Olayinka A, Hernandez-Santana A, Bermingham S and McMahon G. Development of a 
novel method for magnetic bead extraction of Taxanes from serum followed by 
separation and detection by liquid chromatography. Journal of Undergraduate Chemsitry 
Research, currently under review 
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Appendix 2: Conference presentations 
 
Work carried out throughout this thesis was presented in poster form at numerous scientific 
conferences throughout Europe: 
 
 
1. Early research was presented at the Analytical Research Forum (ARF) on 16-19th July, 
2007. This conference took place in University of Strathclyde, Glasgow 
Poster title: Development of a novel LC/MS method for anthracycline and taxane drugs 
with on-line sample extraction. 
Authors: Zalma C, Bermingham S, Regan F, McMahon G. 
 
2. A poster was presented at the HTC, ExTech 10 conference held in Bruges, Belgium on 
Jan 28th to Feb 1st , 2008. 
 The poster title was: On line sample preparation of biological samples for determination 
 of cancer chemotherapy drugs. 
 Authors: Bermingham S, McMahon G and Regan F.  
 
3. Another poster was presented at the 5th Biennial Conference on Analytical Sciences in 
Ireland. This analytical conference was held at the Waterford Institute of Technology, 
Waterford on the 7th May, 2008.  
 Poster title:  Advanced analytical methods for separation of cancer chemotherapy drugs. 
 Authors: Bermingham S, O’Connor R, McMahon G and Regan F. 
 
4. The latest research was presented at the 60th Irish Universities Chemistry Research 
Colloquium on 11- 13th June 2008. The conference was held at University College Cork, 
Cork.  
 Poster title: Column switching for extraction and separation of cancer chemotherapy 
 drugs. 
 Authors: Bermingham S, O’Connor R, McMahon G and Regan F. 
 
5. This research was publically presented was at the Analytical Research Forum (ARF) on 
21- 23rd July, 2008. The ARF was held at the University of Hull, UK. 
 Title: On-line SPE-LC analysis of cancer chemotherapy drugs. 
 Authors: Bermingham S, O’Connor R, McMahon G and Regan F. Callaghan A. 
 
Each conference and seminar attended proved very useful and insightful. It provided a great 
opportunity to network with fellow professionals and to gain an understanding of what type of 
scientific research, especially analytical research was being developed in Ireland and around 
Europe. Presented posters were well received at each conference attended 
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Appendix 3: Training received 
 
 
Throughout this research masters degree I received both formal and in-house training on a 
variety of analytical instruments. I was also trained a little on my teaching skills. 
 
 
• There was an in house LC training programme given by my supervisor Dr. McMahon in 
Sep 2007 at Dublin City University which was designed to familiarise myself with the 
LC software and basic running of the instrument. 
 
• I was trained in Dublin City University on a CE instrument in Jan 2008 by an in house 
technician. This training was designed to show the basic running of CE and how it can be 
used as a separation technique. If a suitable LC method could provide the separation 
required in the anthracycline/taxane method then perhaps a CE method for their 
separation could be developed. 
 
• A course was attended in the National Centre for Sensor Research, Dublin City 
University where the basic principles of operation of a MS were explained and a 
demonstration performed on MS operation. This three-day course was put together by an 
expert consultant in the field. It was run as a training module for people starting off in 
MS analysis. 
 
• I attended a 12 week tutor training programme in Dublin City University from March 
until May 2008 which was designed to help new research students perform their 
demonstrating duties successfully. 
 
• I attended some tutorials and a short course at the HTC, Ex-Tech 10 (Jan 28th until 
Feb1st) conference in Brugge, Belgium. The short course was entitled ‘On-line SPE 
upfront to bioanalytical LC-MS’. The tutorials were entitled: ‘Coupling SPE to LC-MS in 
bioanalysis’, ‘Hyphenated techniques in forensic analysis’ and ‘On-column injection: 
Why not the most accurate and most simple injection technique?’ 
 The tutorials and especially the short course attended were very relevant to the 
sort of analytical research I was working on throughout my project and I found it 
extremely beneficial and helpful. 
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Appendix 4: Relevant experience gained 
 
 
Every scientific research student in Dublin City University has to take part in demonstrating 
duties to help out in practical scientific laboratories for undergraduate students. During my time 
in Dublin City University I taught: 
 
• First year Science Education students between Oct and Dec 2008. I had to demonstrate in 
a classroom environment where the students worked together in groups solving scientific 
problems and generating weekly reports. I would answer any questions a student might 
have and help the students to think logically about any problems they found difficult. I 
also had to grade class reports. 
 
• Masters students doing the MSc in Instrumental Analysis. These mature students took 
night classes in analytical science. This was a lab based practical course in the analysis of 
organic and inorganic species. My duties were to parole the laboratory making sure 
experiments were performed safely and correctly. If a student had a problem with 
instrumentation or its software I would try to help them. I also had to correct weekly 
reports.  
 
I also attended safety courses, lone working training and seminars and talks given by guest and 
visiting lecturers who came to DCU to talk on chemistry and biology topics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
